23rd Annual Meeting and Education Day
Of the Society for Neuro-Oncology
November 15-18, 2018
Marriott Hotel
New Orleans, Louisiana

Meeting Program
SOC-NEURO-ONC.ORG
In patients with newly diagnosed GBM, OPTUNE® + TMZ HAS BEEN PROVEN TO PROVIDE

Survival with Optune® + TMZ vs TMZ alone was significantly better at the 2- and 5-year landmark analyses

- **YEAR 2**
  - Median OS was significantly extended with Optune—by nearly 5 months (P<0.001) ¹
  - Optune + TMZ also significantly improved PFS vs TMZ alone (median PFS: 6.7 months vs 4.0 months, P<0.001) ¹

- **YEAR 5**
  - P (median PFS: 6.7 months vs 4.0 months, <0.001) ¹

Indications For Use
Optune is intended as a treatment for adult patients (22 years of age or older) with histologically-confirmed glioblastoma multiforme (GBM). Optune with temozolomide is indicated for the treatment of adult patients with newly diagnosed, supratentorial glioblastoma following maximal debulking surgery, and completion of radiation therapy together with concomitant standard of care chemotherapy.

Important Safety Information
Contraindications
Do not use Optune in patients with an active implanted medical device, a skull defect (such as, missing bone with no replacement), or bullet fragments. Use of Optune together with implanted electronic devices has not been tested and may theoretically lead to malfunctioning of the implanted device. Use of Optune together with skull defects or bullet fragments has not been tested and may possibly lead to tissue damage or render Optune ineffective.

Do not use Optune in patients that are known to be sensitive to conductive hydrogels. In this case, skin contact with the gel used with Optune may commonly cause increased redness and itching, and rarely may even lead to severe allergic reactions such as shock and respiratory failure.

Warnings and Precautions
Optune can only be prescribed by a healthcare provider that has completed the required certification training provided by Novocure™ (the device manufacturer).

Do not prescribe Optune for patients that are pregnant, you think might be pregnant or are trying to get pregnant, as the safety and effectiveness of Optune in these populations have not been established.

The most common (≥10%) adverse events involving Optune in combination with temozolomide were thrombocytopenia, nausea, constipation, vomiting, fatigue, medical device site reaction, headache, convulsions, and depression.

Use of Optune in patients with an inactive implanted medical device in the brain has not been studied for safety and effectiveness, and use of Optune in these patients could lead to tissue damage or lower the chance of Optune being effective.

If the patient has an underlying serious skin condition on the scalp, evaluate whether this may prevent or temporarily interfere with Optune treatment.
Patients treated with Optune + TMZ maintained QoL over time\(^2,3\)
Both HCPs and patients reported stable QoL evaluation scores up to 1 year of Optune use
- HCP-reported KPS\(^*\) was approximately 90 at baseline and 12 months\(^3\)
- Patient-reported Global Health Status\(^†\) was approximately 70 at baseline and 12 months\(^2\)

Patient image reflects the health status of the patient at the time the photo was taken.
*HCP-reported data collected per Karnofsky Performance Score (KPS) assessment at baseline and then repeated monthly. Patient functional status via KPS (at multiple time points) measured patient independence in activities of daily living.
†Patient-reported data collected per EORTC QLQ-C30 at baseline and Months 3, 6, 9, and 12. This 30-question survey covered 5 daily-functioning domains (Physical, Role, Social, Emotional, and Cognitive).
EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer core quality of life questionnaire; GBM, glioblastoma; OS, overall survival; PFS, progression-free survival; QoL, quality of life; TMZ, temozolomide.


Please visit Optune.com/IFU for Optune Instructions for Use (IFU) for complete information regarding the device’s indications, contraindications, warnings, and precautions.

Visit us at Booth #206 to learn more about putting GBM on pause and life on play

©2018 Novocure. All rights reserved. Optune and Novocure are trademarks of Novocure. OPT-1825
# 23rd Annual Meeting and Education Day of the Society for Neuro-Oncology

## Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Meeting Overview</td>
<td>6</td>
</tr>
<tr>
<td>SNO Committees, Reviewers and Supporters</td>
<td>8</td>
</tr>
<tr>
<td>Ancillary Meetings</td>
<td>10</td>
</tr>
<tr>
<td>Meeting Room and Exhibitor Maps</td>
<td>12</td>
</tr>
<tr>
<td>Poster Maps</td>
<td>14</td>
</tr>
<tr>
<td>Meeting Program</td>
<td>16</td>
</tr>
<tr>
<td>- Thursday</td>
<td>18</td>
</tr>
<tr>
<td>- Friday</td>
<td>20</td>
</tr>
<tr>
<td>- Saturday</td>
<td>32</td>
</tr>
<tr>
<td>- Sunday</td>
<td>44</td>
</tr>
</tbody>
</table>
WELCOME TO NEW ORLEANS!

Dear Colleagues,

We are delighted to welcome you to the 23rd Annual Meeting of the Society for Neuro-Oncology! Held in the vibrant and eclectic city of New Orleans, we expect this year’s meeting will play a vital role in bridging the gap between neuro-oncology research and clinical practice.

Following a pre-conference program on the critically important topic of drug discovery, and the ever-popular Neuro-Oncology Review Course, the 2018 SNO Education Day will focus on “Transforming Clinical Trials in the Modern-Day Era” with keynote lectures from Ronald DePinho and Gideon Blumenthal.

Continuing with the theme of clinical trials, the main scientific program will offer keynote and plenary addresses from Timothy Cloughesy, William Kaelin Jr., Maryam Fouladi and John Sampson. In addition, the Guha Award & Lecture will be delivered by Linda Liau, and the Victor Levin Award & Lecture will be delivered by Antonio Chiocca.

As is typical of the SNO meeting, conference participants will have the opportunity to attend early morning and lunchtime didactic sessions on a broad and varied range of neuro-oncology topics. Outstanding science will be presented in over 200 oral talks selected from the submitted abstracts.

The two evening poster sessions are not to be missed, featuring 45 rapid-fire e-talks and over 400 traditional paper posters each night at the adjacent Sheraton Hotel.

Nicknamed the “Big Easy”, New Orleans is known for its nightlife, exciting live-music scene and Cajun cuisine reflecting its history as a melting-pot of French, Caribbean and American cultures. The city’s wide array of attractions, activities, and personality-infused neighborhoods appeal to visitors of all ages. Against this backdrop, the SNO annual meeting will be an outstanding forum for networking and building lasting relationships with like-minded colleagues from around the world.

We hope you enjoy the meeting and the city of New Orleans!

Sincerely,

Frank Furnari, Daphne Haas-Kogan, Vinay Puduvalli
MEETING OVERVIEW

The 23rd Annual Meeting and Education Day of the Society for Neuro-Oncology will take place at the Marriott Hotel in New Orleans, Louisiana. With a prime location in the heart of the world-famous French Quarter, this impressive hotel lets you experience everything New Orleans is renowned for! Bourbon Street, the Audubon Aquarium, Cafe du Monde, the WWII Museum, and other local attractions are all within easy walking distance.

Building on the success of past SNO meetings, sunrise sessions, plenary and concurrent sessions will be featured with oral abstract presentations, enhanced oral eTalk presentations, and poster presentations. Special lunch tutorials and industry-sponsored symposia will provide in-depth information on evolving technologies and therapeutics. Circulated for viewing throughout the meeting will be webcasts with “Meet the Expert” recordings of esteemed scientists and clinicians. The SNO Daily Highlights will again be recorded for viewing, with invited discussants reviewing the most cutting-edge science from that day’s basic science and clinical research presentations. Interactive ePoster touch screens will be available in a specially designated area of the meeting space.

SNO DAILY HIGHLIGHTS

SNO Daily Highlights will again be featured this year, in which invited discussants will review the most cutting-edge science from that day’s basic science and clinical research presentations. The SNO Daily Highlights will be video-taped and made available for viewing that same evening via the meeting app.

Friday Discussants
Anita Hjelmeland
Marta Penas-Prado

Saturday Discussants
Jennifer Clarke
Annette Molinaro

MEET THE EXPERTS VIDEOS

Be sure to watch SNO’s Meet the Expert Videos, which will be available for viewing throughout the conference area. These 10-minute, videotaped talks by esteemed scientists and clinicians provide an overview of some of the key issues in brain tumor research. This year’s topics include CART T cell technology, neural stem cells, immunotherapy and neurosurgery-CAR T cells for glioblastoma.

Presenters
Yvonne Chen
CAR T Cell Technology
Steve Pollard
Neural Stem Cells
Donald O’Rourke
Neurosurgery-CAR T Cells for Glioblastoma
Dean Lee
Immunotherapy

e-TALKS

Don’t miss this year’s e-Talk sessions on Friday and Saturday evenings. Located in the Sheraton Hotel-Grand Ballroom, these interactive 4-minute oral E-Talk presentations are followed by viewing and discussion in the main poster area.

Friday from 7:30 - 9:30 (See pages 29-31 for full speaker list)

- Group 1: Cell Signaling/Cell Biology/Metabolism/Genetics/Epigenetics
- Group 2: Drug Resistance/Drug Discovery/Experimental Therapeutics/Tumor Microenvironment
- Group 3: Imaging/Pediatric Tumor Models/Pediatric Clinical Trials/Molecular Pathology/Health Outcomes

Saturday from 5:00 - 7:00 (See pages 40-42 for full speaker list)

- Group 1: Adult Therapeutics/Immunology
- Group 2: Angiogenesis and Invasion/Radiation Biology and DNA Repair/Tumor Models/ Stem Cells/Epidemiology
- Group 3: Health Outcomes/Neurological Complications of Cancer and Cancer Therapy/Quality of Life/Radiotherapy/Surgical Therapy/CNS Metastases

SPEAKER READY ROOM

All oral presenters will need to drop off their slides in the Speaker Ready Room located in Bonaparte (4th Floor) if they did not previously upload them via the web. Check your email for presentation requirements.

INTERNET ACCESS

Wi-Fi is available in the main conference rooms and foyer areas.
Network name: SNOMeeting Password: SNO2018wifi

Charging stations for mobile devices can be found in the foyer areas of the Preservation Hall.

SNO CAREER LOUNGE

The “SNO Career Lounge” facilitates a convenient environment where prospective candidates and employers can connect. The Career Lounge is located in Preservation Hall (2nd Floor) of the Marriott Hotel, and will be open Thursday, Friday and Saturday, from 10:00am to 4:00pm. Scheduling of interviews may be arranged by contacting the Career Lounge Coordinators, Sheela Purandhara and Takyee Tung at SNOcareerlounge@gmail.com.

SNO APP

Download the official SNO meeting app and put everything you need to know about this year’s conference right into the palm of your hand. Customize your conference experience by creating your schedule in advance, communicate with other attendees, view posters, text questions to moderators, and take session notes. Access the Attendee Directory to connect with new acquaintances, browse the scientific abstracts, claim CME, and view daily video previews/highlights of the day.

The SNO meeting app is currently available in the App Store and Android Market; simply search for “SNO Annual Meeting”. There will also be a dedicated app assistance booth on site in New Orleans if you need further technological assistance.

Please sign-in using the same username and password that was used to register for the Conference to access the mobile app. Visit booth #300 if you need assistance!

NEW THIS YEAR!

The SNO meeting will provide some exciting new features this year including:
- VIEW POSTERS ON YOUR MOBILE DEVICE
- EXPANDED OPPORTUNITIES FOR Q&A
- MORE SUNRISE SESSION TOPICS
- ENHANCED FEATURES AND NEW NAVIGATION ON APP
- PRESENTATION UPLOAD PRIOR TO THE MEETING
- CAPTURE OF ALL CONTENT FOR POST-MEETING EDUCATION SITE
GALA DINNER
Laissez les bons temps rouler! Join your colleagues from around the world for a special evening to experience a taste—literally and figuratively—of the fascinating culture and delicious cuisine of New Orleans. The evening begins as we gather for libations in front of the Marriott Hotel, and then proceed to parade through the streets of New Orleans, escorted by police, stilt walkers, costumed performers and a raucous brass band. The parade route will take us down Canal Street and through the Warehouse District, dancing and throwing beads to passers-by along the way! Our parade will terminate at the New Orleans Contemporary Arts Center, where we will be treated to delicious Cajun cuisine and lively music for the remainder of the evening!

EDUCATIONAL OBJECTIVES
After attending this conference, participants should be able to:
• Discuss new CNS cancer technologies in the areas of cell biology, cell signaling, genetics, epigenetics, immune-based therapies including CAR T therapy, stem cells, metabolomics, tumor microenvironment, lower grade gliomas, radiobiology and radiomics, synthetic lethal strategies, and viral therapy,
• Implement higher quality clinical trials based on an understanding of strategies for choosing which therapies to evaluate in specific patient populations,
• Apply novel trial designs beyond the traditional phase I, II and III studies for more efficient evaluation of target drugs,
• Identify obstacles to clinical trial enrollment and discuss technologies to increase accessibility and data capture,
• Incorporate new endpoints in clinical trials that measures what is of most importance to patients,
• Describe new advances in the treatment of CNS metastases,
• Utilize patient reported outcomes to evaluate net clinical benefits for patients undergoing treatment,
• Apply information on sexual differences in brain tumors and reproductive and women’s issues to efficiently address therapeutic implications.

TARGET AUDIENCE
The SNO annual meeting will be of value to neuro-oncologists, medical oncologists, adult and pediatric neurosurgeons, pediatric neuro-oncologists, neuroradiologists, neuropathologists, radiation oncologists, neuro-psychologists, epidemiologists, basic and translational scientists and allied health professionals.

EDUCATIONAL METHODS
Lectures, Question-and-Answer Sessions, Panel Discussions, Posters, etc.

EVALUATION
A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

ACCREDITATION/CREDIT DESIGNATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of The University of Texas MD Anderson Cancer Center and the Society for Neuro-Oncology. The University of Texas MD Anderson Cancer Center is accredited by the ACCME to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 26.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

CME CERTIFICATES AND ATTENDANCE VERIFICATION CERTIFICATES
Certificates awarding AMA PRA Category 1 Credit™ will only be available online via the SNO app and/or website. These will be available from the start of the meeting through 4 weeks following the end of the meeting. Physicians will be directed to the evaluation questionnaire and a CME Verification Form which must be completed prior to the CME certificate being displayed. Once displayed the certificate may be printed or downloaded. An email address may also be entered to send the certificate. A record of the CME certificate will be saved for future access.

Certificates of attendance will also be available online via the app and/or website for other health care professionals and international faculty upon completion of the evaluation form. This certificate may be used in verifying attendance or for requesting credits with state nursing boards, specialty societies or other professional associations. A record of this certificate will be saved for future access.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially influence the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity. Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.
2018 SNO OFFICERS

President
Patrick Wen

Vice President
Gelareh Zadeh

Secretary-Treasurer
Tracey Batchelor

Board of Directors
Christina Amidei
Priscilla Brastianos
Daniel Brat
Nicholas Butowski
Ian Dunn
Annette Molinaro
Michelle Monje
Whitney Pope
Solmaz Sahebjam
Erik Sulman
Michael Taylor

Past President
E. Antonio Chiocca

Foundation Board
Victor A. Levin (SNO Founder)
Mitchel S. Berger
Susan Chang
David Reardon

Neuro-Oncology
Kenneth Aldape (Editor-in-Chief)
Patrick Wen (SNO Executive Editor)

Neuro-Oncology Practice
Susan Chang (Editor-in-Chief)
Jeffrey Wefel (SNO Editor)

WFNOS Magazine
Nicholas Butowski (SNO Editor)

SNO STAFF

Executive Director
J. Charles Haynes

Manager, Member & Program Services
Linda Greer

Manager of Medical Education
Carolyn Loch

Manager of Medical Education
Tara Alexander

Marketing & Exhibits Coordinator
Megan Bell-Johnston

Manager of Technology Integration
Ginger Vazquez

Manager of Program Events
Shelley Pressley

Communications Coordinator
Kristin Odom

Bookkeeper
Martha Maloch

SCIENTIFIC COMMITTEE

Scientific Meeting Chairs
Frank Furnari
Daphne Haas-Kogan
Vinay Puduvalli

Education Day Chairs
Brian Alexander
Ingo Mellinighoff
Joohee Sul
Martin Taphoorn

Awards Committee
Manish Aghi
Frank Furnari
Daphne Haas-Kogan

Poster Awards Committee
Krishna Bhat
Zev Binder
David Cachia
Mariella Filbin
Craig Horbinski
Jason Huse
Carolos Kamyia
Balveen Kaur
Santosh Kesari
Sylvia Kurz
Katherine Nevel
Reena Thomas

INTERNATIONAL OUTREACH TRAVEL SCHOLARSHIP RECIPIENTS

Marinaela Candolfi
University of Buenos Aires, Argentina

Carlos D. Giménez Méndez
Hospital de Clinicas, Paraguay

Mehmet Kantar
EGE University Hospital, Turkey

Paul Vincent Opinado
St. Luke's Medical Center, Philippines

Hoai an Hoang Nguyen
Hue Central Hospital, Viet Nam

Qixue Wang
Tianjin Medical University General Hospital, China

Supriya Mallick
All India Institute of Medical Sciences, India

Anish Man Singh
Nepal Cancer Hospital and Research Center, Nepal

Khristyna Zapotochna
Western Ukraine Specialized Children’s Medical Centre, Ukraine

PLATINUM SUPPORTERS

The Society for Neuro-Oncology gratefully acknowledges the SNO Platinum Partners listed below. Their on-going support allows SNO to fulfill its mission to advance neuro-oncology research and education.

AbbVie
American Brain Tumor Association
AstraZeneca
Bristol-Myers Squibb
National Brain Tumor Society
Novocure
Sontag Foundation

MEETING SUPPORTERS

The Society for Neuro-Oncology wishes to express appreciation to the organizations listed below for their promotional support of this meeting.

Benefactor Level
Brainlab
CERN Foundation
Nativis
Orbus Therapeutics

Contributor Level
BeiGene
Celgene
EndBrainCancer Initiative
Genentech
Illumina
Northwest Biotherapeutics
Tocagen

EDUCATIONAL SUPPORTERS

The conference organizing committee wishes to express appreciation to the following companies for their commitment to continuing medical education by providing an educational grant in support of this conference:

AbbVie
Celgene
ABSTRACT REVIEWERS

Meera Agar
Manish Aghi
Manmeet Ahluwalia
Kenneth Aldape
Elizabeth Algar
Christina Amidei
Yoshiki Arakawa
Hideyuki Arita
Terri Armstrong
Isabel Arrillaga
Simon Bailey
Fred Barker
Jill Barnholtz-Sloan
Oren Becher
Susan Bell
Etty Benveniste
Michael Berens
Anna Berghoff
Krishna Bhat
Orin Bloch
Adrienne Boire
Eric Bouffet
Priscilla Brastianos
Daniel Brat
Steve Braunstein
Severa Bunda
Nicholas Butowski
Daniel Cahill
Jennifer Cahill
Susan Chang
Al Charest
Shiyuan Cheng
Lawrence Cher
Milan Chheda
Chi Chi
Oliver Chint
Jennifer Clarke
Elizabeth Claus
Steve Clifford
Rivka Colen
Howard Colman
Denise Correa
Joseph Costello
Faith Davis
Bryan Day
John de Groot
Lisa DeAngelis
Aaron Diaz
Jorg Dietrich
Jan Drappatz
Gavin Dunn
Charles Eberhart
Jeanette Eckel-Passow
David Eisenstat
Benjamin Ellingson
Peter Fecci
Olavo Feher
Kathryn Field
Howard Fine

MONITORS

Arlet Acanda de la Rocha
Iyad Alnahhas
Ian Bargha
Define Bayik
Monica Butler
Luis Castro
Jie Chen
Alberto Delaidelli

Jonathan Finlay
John Fiveash
Ekobe Fonkem
Deborah Forst
Takamitsu Fujimaki
Frank Furnari
Amar Gajjar
Eva Galanis
Norbert Galldiks
Hui Gan
Na Toshia Gatson
Pierre Giglio
Mark Gilbert
Jakub Godlewski
Wolfgang Grisold
Christian Grimes
Deliang Guo
Cecelia Gzella
Daphne Haas-Kogan
Constantine Hadjipanayis
Monika Hegi
John Henson
Shawn Hervey-Jumper
Christopher Hess
Yuichi Hirose
Craig Horbinski
Matthew Hunt
Jason Huse
Nada Jabado
Kurt Jaekle
Asgeir Jakola
Rakesh Jalali
David James
Lindy Jeffree
Sarah Jeffries
Robert Jenkins
Michael Jenkinson
Randi Jensen
Terrance Johns
Chris Jones
Benjamin Jonker
Justin Jordan
Balveen Kaur
Santosh Kesari
Rajiv Khanna
Mustafa Khasaw
Soumen Khatua
Phlipck Kickingderer
Manabu Kinoshita
Cassie Kline
Takashi Komori
Paul Kongkhams
John Kuo
Albert Lai
Katrin Lamszus
Danette Langbecker
Justin Lathia
Gordon Li
Michael Lim

Mary Lovely
Zhimin Lu
Janinen Lupo
Anita Mahajan
Elizabeth Maher
Marcos Maldon
Aaron Mammesser
Suey Maymone-Melo
Catherine Mcbain
Kerrie McDonald
Minesh Mehta
Ryan C. Miller
Paul Mischel
Duane Mitchell
Sandra Mitchell
Annette Molinaro
Sabine Mueller
Akitake Mukasa
Burt Nabor
Motoo Nagane
Seema Nagpal
Brian Nahed
Mitsutoshi Nakada
Jean Nakamura
Ichiro Nakano
Atsushi Natsume
Lakshmi Nayak
Simone Niclou
Theo Nicolaides
Ryo Nishikawa
Paul Northcott
Anna Nowak
Nancy Ann Oberheim-Bush
Makoto Ohno
Hideho Okada
Patrick Padding
Joshua Palmer
Chul-Kee Park
Jonathon Parkinson
Michael Parsons
Marta Penas-Prado
Arie Perry
James Perry
Jennifer Phillips
Joanna Phillips
Russell Pieper
Mark Pinkham
Marshall Pitz
Scott Pomeroy
Whitney Pope
Vinay Puduvalli
Eudoxia Quant-Lee
Ruman Rahman
Jeffrey Raizer
David Raleigh
Rohan Ramakrishna
Otto Rapalino
Raju Raval
David Readon

Monstserrat Lara-Velazquez
Victor Lu
Emmanuel Mantilla Jr.
Nicholas Metrus
Malte Mohme
Alankrita Raghavan
Prasanth Romiyo
Ashley Roque

Brent Reynolds
Jeremy Rich
David Roberge
Michael Rodrigues
Lisa Rogers
Sabrina Ronen
Alasdair Rooney
Mark Rosenthal
James Rubenstein
Susan Salas
Jann Sarkaria
Hikaru Sasaki
Sith Sathornsumetee
Adrienns Scheck
Nils Ole Schmidt
Soma Sengupta
Wenyan Shi
Stephanie Shook-Pugh
Shelia Singh
Tania Slatter
Sonoda Yukihiro
Charles Stiles
Roger Stupp
Erik Sulman
Mario Suva
Ghazaleh Tabatabai
Bakhos Tannous
Jennie Taylor
Michael Taylor
Carina Thomé
Joerg-Christian Tonn
Joon Uhm
Martin van den Bent
Monica Venere
Roel Verhaak
Michael Vogelbaum
Derek Wainwright
Tobias Walbert
David Walker
Kyle Walsh
Zhaohui Wang
Shiao-Pei Weathers
Jeffrey Wefel
William Weiss
Mary Welch
Michael Weller
Patrick Wen
Leonardo Wendling
Cynthia Wetmore
Wolfgang Wick
Margaret Wrench
Jing Wu
Fen Xia
Fumiyuki Yamasaki
Stephen Yip
Koji Yoshimoto
Gelareh Zadeh
Jay-Jiguang Zhu
David Ziegler

23rd Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology

Brian Shaw
Andrew Song
Catherine Stangherlin
Shinji Strain
Elavarasan Subramani
Aria Tarudji
Sebastian Winter
## ANCILLARY & COMMITTEE MEETINGS

### Wednesday, November 14, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Function</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>4:00-6:00pm</td>
<td>CARE/HOPE Steering Committee Meeting</td>
<td>Balcony J</td>
</tr>
<tr>
<td>5:00-7:00pm</td>
<td>GDC-0084 GBM Study Investigator Meeting</td>
<td>Balcony L</td>
</tr>
<tr>
<td>6:30-8:30pm</td>
<td>Allied Health Networking Reception</td>
<td>Riverview I-II</td>
</tr>
</tbody>
</table>

### Thursday, November 15, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Function</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00-8:00am</td>
<td>Allied Health Breakfast Networking Session</td>
<td>Galeries 5-6</td>
</tr>
<tr>
<td>7:00am-7:00pm</td>
<td>PNOC PI Fall Meeting</td>
<td>Balcony I-J</td>
</tr>
<tr>
<td>7:30am-3:30pm</td>
<td>Boehringer Ingelheim Pharmaceuticals</td>
<td>Balcony K</td>
</tr>
<tr>
<td>12:00-1:00pm</td>
<td>SNO Guidelines Committee Meeting</td>
<td>Balcony M</td>
</tr>
<tr>
<td>12:05-1:05pm</td>
<td>Women in Neuro-Oncology (WIN) Committee Luncheon</td>
<td>Galeries 5-6</td>
</tr>
<tr>
<td>12:00-6:30pm</td>
<td>Blue Earth Diagnostics Advisory Board Luncheon</td>
<td>Bacchus</td>
</tr>
<tr>
<td>3:30-5:30pm</td>
<td>ERC Scientific Advisory Board Meeting</td>
<td>Lafayette</td>
</tr>
<tr>
<td>5:30-7:30pm</td>
<td>NCI Brain Malignancies Steering Committee Meeting</td>
<td>Balcony K</td>
</tr>
<tr>
<td>5:30-7:30pm</td>
<td>SNO Board of Directors Meeting</td>
<td>Galeries 5-6</td>
</tr>
<tr>
<td>6:00-8:00pm</td>
<td>Laraciclib Investigator Meeting</td>
<td>Iberville</td>
</tr>
<tr>
<td>7:30-8:30pm</td>
<td>CERN Reception</td>
<td>Riverview II</td>
</tr>
<tr>
<td>7:30-8:30pm</td>
<td>Young Investigator’s Career Development and Networking Session</td>
<td>Mardi Gras A-D</td>
</tr>
</tbody>
</table>

### Friday, November 16, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Function</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30-8:30am</td>
<td>Tocagen Advisory Board Meeting</td>
<td>Balcony I</td>
</tr>
<tr>
<td>7:00-8:00am</td>
<td>CATNON TR Meeting</td>
<td>Balcony K</td>
</tr>
<tr>
<td>7:00-8:30am</td>
<td>Glioma Southeast Epidemiological Group</td>
<td>Balcony L</td>
</tr>
<tr>
<td>8:00-9:00am</td>
<td>SNO Public Policy</td>
<td>Iberville</td>
</tr>
<tr>
<td>12:15-1:15pm</td>
<td>SNO Young Investigator Luncheon</td>
<td>Riverview II</td>
</tr>
<tr>
<td>5:00-6:00pm</td>
<td>Neuro-Oncology Fellowship Program Directors Meeting</td>
<td>Mardi-Gras F-H</td>
</tr>
<tr>
<td>5:30-6:30pm</td>
<td>Neuro-Palliative Meet-Up</td>
<td>Iberville</td>
</tr>
<tr>
<td>5:30-7:30pm</td>
<td>2018 MD Anderson Neuro-Oncology Fellowship Reception</td>
<td>Riverview I</td>
</tr>
<tr>
<td>5:30-7:30pm</td>
<td>MGH/DFCI/BWH Neuro-Oncology Fellowship Reception</td>
<td>Balcony J</td>
</tr>
<tr>
<td>5:30-7:30pm</td>
<td>Tocagen Reception</td>
<td>Balcony I</td>
</tr>
<tr>
<td>7:00-10:00pm</td>
<td>Agios Reception</td>
<td>Balcony K</td>
</tr>
<tr>
<td>7:30-9:30pm</td>
<td>The Glioma Longitudinal Analysis Consortium</td>
<td>Mardi Gras A-B</td>
</tr>
<tr>
<td>9:30-11:00pm</td>
<td>SNO Invited Faculty Reception</td>
<td>Riverview I-II</td>
</tr>
</tbody>
</table>

### Saturday, November 17, 2018

<table>
<thead>
<tr>
<th>Time</th>
<th>Function</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:30-8:30am</td>
<td>Neuro-Oncology Practice Editorial Board Meeting</td>
<td>Galerie 3</td>
</tr>
<tr>
<td>7:00-8:30am</td>
<td>Tocagen Advisory Group Breakfast</td>
<td>Balcony I</td>
</tr>
<tr>
<td>12:15-1:15pm</td>
<td>ABMC Fall Follow Up Meeting</td>
<td>Bacchus</td>
</tr>
<tr>
<td>12:15-1:15pm</td>
<td>Neuro-Oncology Trainee Forum</td>
<td>Balcony J</td>
</tr>
<tr>
<td>12:15-1:15pm</td>
<td>SNO International Outreach Luncheon</td>
<td>Galerie 4</td>
</tr>
<tr>
<td>1:30-3:30pm</td>
<td>Neuro-Oncology Editorial Board Meeting</td>
<td>Balconies M-N</td>
</tr>
<tr>
<td>5:00-7:00pm</td>
<td>Advances of Neuro-Oncology Research in China</td>
<td>Mardi Gras A-B</td>
</tr>
<tr>
<td>5:00-7:00pm</td>
<td>Investigator Meeting: H3 K27M Trial</td>
<td>Balcony J</td>
</tr>
<tr>
<td>5:00-8:00pm</td>
<td>Nativis Business Meeting</td>
<td>St. Charles</td>
</tr>
<tr>
<td>6:00-7:00pm</td>
<td>SNO Partners Advisory Meeting</td>
<td>Galerie 3</td>
</tr>
</tbody>
</table>
POSTERS   Saturday, November 17, 2018
Sheraton Hotel  Grand Ballroom

Abbreviations and categories for legend

ACTR - Adult Clinical Trials – Non-immunologic
ANGI - Angiogenesis and Invasion
ATIM - Adult Clinical Trials – Immunologic
CBMT - Cell Biology and Metabolism
CMET - CNS Metastasis
COMP - Computational Omics
CSIG - Cell Signaling and Signaling Pathways
DDIS - Drug Discovery
DRES - Drug Resistance
EPID - Epidemiology
EXTH - Experimental Therapeutics
GENE - Genetics and Epigenetics
HOUT - Health Outcome Measures
IMMU - Immunology
INNV - Innovations in Patient Care
MNGI - Meningioma
NCMP - Neurological Complications of Cancer and Cancer Therapy
NCDG - Neuro-Cognitive Outcomes
NIMG - Neuro-Imaging
PATH - Molecular Pathology and Classification – Adult and Pediatric
PDCT - Pediatric Clinical Trials
PDTM - Pediatric Tumors
QOLP - Quality of Life and Palliative Care
RARE - Rare Tumors
RBTT - Randomized Brain Tumor Trials in Development
RDNA - Radiation Biology and DNA Repair
RTHP - Radiation Therapy
STEM - Stem Cells
SURG - Surgical Therapy
TMIC - Tumor Microenvironment
TMOD - Tumor Models
CADD - CNS Anticancer Drug Discovery and Development
# Program at a Glance

**Thursday, November 15, 2018**  
*Education Day*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 - 8:10am</td>
<td>Welcome and Introduction</td>
<td>Grand Ballroom Acadia - Bissonet</td>
</tr>
<tr>
<td>8:10 - 8:40am</td>
<td>Keynote Presentation: Ronald DePinho</td>
<td></td>
</tr>
<tr>
<td>8:40 - 10:15am</td>
<td>Session 1 - Cancer Biology and Genomics</td>
<td></td>
</tr>
<tr>
<td>10:15 - 10:30am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:05am</td>
<td>Session 2 - Clinical Trials Basics</td>
<td></td>
</tr>
<tr>
<td>12:05 - 12:10pm</td>
<td>Lunch</td>
<td></td>
</tr>
<tr>
<td>12:10 - 1:30pm</td>
<td>Keynote Presentation: Gideon Blumenthal</td>
<td></td>
</tr>
<tr>
<td>1:30 - 3:30pm</td>
<td>Session 3 - Next-generation Trials and Biomarkers</td>
<td></td>
</tr>
<tr>
<td>3:30 - 3:45pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:45 - 5:15pm</td>
<td>Session 4 - Improving Patient Participation in Clinical Trials</td>
<td></td>
</tr>
<tr>
<td>5:15pm</td>
<td>Adjourn</td>
<td></td>
</tr>
<tr>
<td>5:15 - 7:30pm</td>
<td>Town Hall Meeting</td>
<td>Grand Ballroom Acadia - Bissonet</td>
</tr>
<tr>
<td>7:30 - 10:00pm</td>
<td>Welcome Reception</td>
<td>Marriott Porte-coche’re (Street Level)</td>
</tr>
</tbody>
</table>

**Friday, November 16, 2018**  
*Main Meeting*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:05am</td>
<td>Welcome and Introduction</td>
<td>Grand Ballroom</td>
</tr>
<tr>
<td>9:35 - 10:05am</td>
<td>Keynote Presentation: Maryam Fouladi</td>
<td></td>
</tr>
<tr>
<td>10:05 - 10:20am</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:20 - 10:55am</td>
<td>Victor Levin Award: E. Antonio Chiocca</td>
<td></td>
</tr>
<tr>
<td>10:55 - 11:20am</td>
<td>Presidential Address: Patrick Wen</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:30am</td>
<td>SNO Membership Survey and Convention Center Transition: Gelareh Zadeh and Chas Haynes</td>
<td></td>
</tr>
<tr>
<td>11:30 - 12:00pm</td>
<td>Top Scoring Abstracts</td>
<td></td>
</tr>
<tr>
<td>12:15 - 1:15pm</td>
<td>Lunch - Lunchtime Tutorials and Educational Sessions / Independent Supported Symposium</td>
<td></td>
</tr>
<tr>
<td>1:30 - 3:00pm</td>
<td>CONCURRENT SESSION 2A: Adult Clinical Trials I / Trials in Development</td>
<td>Ballroom Acadia-Bissonet</td>
</tr>
<tr>
<td>1:30 - 3:00pm</td>
<td>CONCURRENT SESSION 2B: Practical and Applied Neuro-Oncology</td>
<td>Ballroom Carondelet</td>
</tr>
<tr>
<td>1:30 - 3:00pm</td>
<td>CONCURRENT SESSION 2C: Experimental Therapeutics</td>
<td>Mardi Gras D-E</td>
</tr>
<tr>
<td>3:00 - 3:15pm</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>3:15 - 5:00pm</td>
<td>CONCURRENT SESSION 3A: Immunology - Preclinical and Clinical I</td>
<td></td>
</tr>
<tr>
<td>3:15 - 5:00pm</td>
<td>CONCURRENT SESSION 3B: Genetics/Epigenetics /Computational Omics</td>
<td></td>
</tr>
<tr>
<td>3:15 - 5:00pm</td>
<td>CONCURRENT SESSION 3C: Microenvironment/ Angiogenesis/Invasion</td>
<td></td>
</tr>
<tr>
<td>5:00 - 7:00pm</td>
<td>Factors Impacting Clinical Trial Accrual - A SNO/RANO Initiative</td>
<td>Grand Ballroom Acadia-Bissonet</td>
</tr>
<tr>
<td>5:30 - 7:30pm</td>
<td>Independent Supported Symposia</td>
<td></td>
</tr>
<tr>
<td>7:30 - 9:30pm</td>
<td>E-TALKS and POSTER SESSION</td>
<td>Sheraton Hotel - Grand Ballroom</td>
</tr>
</tbody>
</table>
## PROGRAM AT A GLANCE

**Saturday, November 17, 2018  Main Meeting**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:05am</td>
<td>Welcome/In Memoriam</td>
<td>Grand Ballroom Acadia - Bissonet - Carondelet</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:05 - 9:35am</td>
<td>Keynote Presentation: Timothy Cloughesy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:35 - 10:05am</td>
<td>Keynote Presentation: John H. Sampson</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:05 - 10:20am</td>
<td>Break</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:20 - 10:50am</td>
<td>Abhijit Guha Award: Linda Liau</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:00am</td>
<td>Lifetime Achievement Award: Gregory Cairncross</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:10am</td>
<td>Neuro-Oncology Community Service Award: David Arons</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:10 - 11:20am</td>
<td>Jan Esenwein Public Service Award: Chas Haynes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:20 - 12:00pm</td>
<td>Top Scoring Abstracts</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:15 - 1:15pm</td>
<td>Lunch - Lunchtime Tutorials and Educational Sessions / Independent Supported Symposium</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| 1:30 - 3:00pm    | Ballroom Acadia-Bissonet | CONCURRENT SESSION 5A: Metabolomics/Cell Biology/Cell Signaling | Ballroom Carondelet | CONCURRENT SESSION 5B: Surgery/Radiation/Radiobiology and DNA Repair | Mardi Gras D-E | CONCURRENT SESSION 5C: Neuro-Imaging |
| 3:00 - 3:15pm    | Break | | Break | Break | |
| 3:15 - 5:10pm    | Ballroom Acadia-Bissonet | CONCURRENT SESSION 6A: Pediatrics: Clinical and Basic Science | Ballroom Carondelet | CONCURRENT SESSION 6B: Meningioma | Mardi Gras D-E | CONCURRENT SESSION 6C: RANO Update |
| 5:00 - 7:00pm    | Independent Supported Symposium | | | | |
| 5:00 - 7:00pm    | E-TALKS and POSTER SESSION | Sheraton Hotel - Grand Ballroom | | | |
| 7:00 - 11:00pm   | SNO GALA Contemporary Arts Center | | | | |

## Sunday, November 18, 2018  Main Meeting

<table>
<thead>
<tr>
<th>SUNRISE SESSIONS</th>
<th>7:00 - 8:30am</th>
<th>Brain Tumor Stem Cells as Drivers of Therapeutic Resistance Ballroom Carondelet</th>
<th>Viral Therapies in Brain Tumors Ballroom Acadia</th>
<th>The Use of Machine Learning Methods in Brain Tumor Imaging Galeries 1-2</th>
<th>Reproductive and Women’s Neuro-Oncology Mardi Gras D-E</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Targeting Gliomas, Perspective from China Galeries 5-6</td>
<td>Circulating Biomarkers Ballroom Bissonet</td>
<td>Meningiomas: Molecular Advances and Targeted Therapy Ballroom Carondelet</td>
<td></td>
</tr>
<tr>
<td>8:45 - 10:15am</td>
<td>Ballroom Acadia-Bissonet</td>
<td>CONCURRENT SESSION 7A: Adult Clinical Trials II</td>
<td>Ballroom Carondelet</td>
<td>CONCURRENT SESSION 7B: Molecular Pathology/Stem Cells</td>
<td>Mardi Gras D-E</td>
</tr>
<tr>
<td>10:15 - 10:30am</td>
<td>Break</td>
<td></td>
<td>Break</td>
<td>Break</td>
<td></td>
</tr>
<tr>
<td>10:30 - 12:15pm</td>
<td>CONCURRENT SESSION 8A: Drug Discovery/Drug Resistance/Tumor Models</td>
<td></td>
<td>CONCURRENT SESSION 8B: Practical and Applied Neuro-Oncology II</td>
<td></td>
<td>CONCURRENT SESSION 8C: Immunology - Preclinical and Clinical II</td>
</tr>
<tr>
<td>12:15 - 12:30pm</td>
<td>Highlights of SNO 2018 and Announcement of Poster Awards</td>
<td></td>
<td></td>
<td></td>
<td>Grand Ballroom Acadia-Bissonet</td>
</tr>
<tr>
<td>12:30pm</td>
<td>Adjourn</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Education Day

## Transforming Clinical Trials in the Modern-Day Era

*Education Chairs:* Brian Alexander, Ingo Mellinghoff, Joohee Sul, Martin Taphoorn

*Supported by the American Brain Tumor Association and Celgene*

---

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:00 - 7:00am</td>
<td>MORNING YOGA</td>
<td>Riverview II</td>
</tr>
<tr>
<td>7:00 - 8:00am</td>
<td>LIGHT CONTINENTAL BREAKFAST</td>
<td>Preservation Hall</td>
</tr>
<tr>
<td>7:00 - 8:00am</td>
<td>Allied Health Breakfast Networking Session</td>
<td>Galeries 5-6</td>
</tr>
<tr>
<td>8:00 - 8:10am</td>
<td>Welcome and Introduction</td>
<td>Grand Ballroom Acadia - Bissonet</td>
</tr>
<tr>
<td></td>
<td><em>Ingo Mellinghoff, Joohee Sul, Martin Taphoorn</em></td>
<td></td>
</tr>
<tr>
<td>8:10 - 8:40am</td>
<td>Keynote Presentation: Global view of cancer</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Ronald DePinho</em></td>
<td></td>
</tr>
<tr>
<td>8:40 - 10:15am</td>
<td>Session 1 – Cancer Biology and Genomics</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Session Chair: Ingo Mellinghoff</em></td>
<td></td>
</tr>
<tr>
<td>8:40 - 9:00am</td>
<td>Aberrant signaling in brain tumors</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Ingo Mellinghoff</em></td>
<td></td>
</tr>
<tr>
<td>9:00 - 9:20am</td>
<td>Molecular trajectories of glioma</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Roel Verhaak</em></td>
<td></td>
</tr>
<tr>
<td>9:20 - 9:40am</td>
<td>Engineering cancer: How to build a brain tumor model</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Suzanne Baker</em></td>
<td></td>
</tr>
<tr>
<td>9:40 - 10:00am</td>
<td>Harnessing large-scale genomic data for cancer gene discovery and therapy</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Nikolaus Schultz</em></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:15am</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>All of Above</em></td>
<td></td>
</tr>
<tr>
<td>10:15 - 10:30am</td>
<td>BREAK</td>
<td>Preservation Hall</td>
</tr>
<tr>
<td>10:30 - 12:05pm</td>
<td>Session 2 – Clinical Trials Basics</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Session Chair: Joohee Sul</em></td>
<td></td>
</tr>
<tr>
<td>10:30 - 10:50am</td>
<td>Clinical trials 101</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Jennifer Clarke</em></td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:10am</td>
<td>Designs for small patient populations</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Karla Ballman</em></td>
<td></td>
</tr>
<tr>
<td>11:10 - 11:30am</td>
<td>Endpoints for clinical trials</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Joohee Sul</em></td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:50am</td>
<td>Pitfalls in oncology drug development</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Patrick Wen</em></td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:05pm</td>
<td>Panel Discussion</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>All of Above</em></td>
<td></td>
</tr>
<tr>
<td>12:05 - 1:05pm</td>
<td>LUNCH</td>
<td>Preservation Hall</td>
</tr>
<tr>
<td></td>
<td><em>Women in Neuro-Oncology (WiN) Committee Luncheon</em></td>
<td>Galeries 5-6</td>
</tr>
<tr>
<td>1:05 - 1:35pm</td>
<td>Keynote Presentation: Novel precision medicine trial designs - Oncology Center of Excellence perspectives</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Gideon Blumenthal</em></td>
<td></td>
</tr>
<tr>
<td>1:35 - 3:30pm</td>
<td>Session 3 – Next-generation Trials and Biomarkers</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Session Chairs: Ingo Mellinghoff, Joohee Sul</em></td>
<td></td>
</tr>
<tr>
<td>1:35 - 1:55pm</td>
<td>Methylation signatures</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Stefan Pfister</em></td>
<td></td>
</tr>
</tbody>
</table>
**EDUCATION DAY  THURSDAY, NOVEMBER 15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1:55 - 2:15pm | Imaging biomarkers in glioma multicenter clinical trials  
**Benjamin Ellingson** |
| 2:15 - 2:35pm | Digital technology: Digital biomarkers, outcomes, and performance measures  
**Andrea Coravos** |
| 2:35 - 2:56pm | Novel clinical trial designs  
**Howard Colman** |
| 2:55 - 3:15pm | Clinical trials: A view from pharma  
**Lauren Abrey** |
| 3:15 - 3:30pm | Panel Discussion  
**All of Above** |
| 3:30 - 3:45pm | BREAK  
**Preservation Hall** |
| 3:45 - 5:15pm | **Session 4 – Improving Patient Participation in Clinical Trials**  
**Session Chair: Martin Taphoorn** |
| 3:45 - 4:05pm | Practitioners views on clinical trials - survey results  
**Terri Armstrong** |
| 4:05 - 4:25pm | Access to trials - the BTN experience  
**Frederick B. Sontag** |
| 4:25 - 4:45pm | Clinical outcomes assessments / RANO COA  
**Martin Taphoorn** |
| 4:45 - 5:15pm | Panel Discussion  
**All of above plus David Arons, David Jenkinson, Liz Salmi, and Kay Verble** |
| 5:15pm       | ADJOURN                                                                                     |
| 5:15 - 7:30pm | **TOWN HALL MEETING: Hot topics in neuro-oncology - Light refreshments at 5:15pm**  
**Grand Ballroom Acadia - Bssonet**  
**Moderator: Burt Nabors**  
- Drug repurposing, **Howard Colman, TBD**  
- Low grade glioma treatment, **Andrew Lassman, TBD**  
- “Right to try” legislation, **Heidi Phillips, David Arons** |
| 7:30 - 10:00pm | **WELCOME RECEPTION**  
**Marriott Porte-coche’re (Street Level)**  
**Supported by Orbus Therapeutics** |
| 7:30 - 8:30pm | **Young Investigator’s Career Development and Networking Session**  
**Mardi Gras A-D**  
(Pre-registration required.) |

**ABSTRACT CODES**

- ACTR: Adult Clinical Trials – Non-immunologic
- ANGI: Angiogenesis and Invasion
- ATIM: Adult Clinical Trials – Immunologic
- CBMT: Cell Biology and Metabolism
- CMET: CNS Metastasis
- COMP: Computational Omics
- CSIG: Cell Signaling and Signaling Pathways
- DDIS: Drug Discovery
- DRES: Drug Resistance
- EPID: Epidemiology
- EXTH: Experimental Therapeutics
- GENE: Genetics and Epigenetics
- HOIT: Health Outcome Measures
- IMMU: Immunology
- INNV: Innovations in Patient Care
- LTBK: Late-Breaking
- MNGI: Meningioma
- NCMP: Neurological Complications of Cancer and Cancer Therapy
- NCOG: Neuro-Cognitive Outcomes
- NIMG: Neuro-Imaging
- PATH: Molecular Pathology and Classification – Adult and Pediatric
- PACT: Pediatric Clinical Trials
- PDM: Pediatric Developmental Malignancies
- PDRM: Pediatric Radiobiology and Molecular Imaging
- POTM: Pediatric Tumors
- QOL: Quality of Life and Palliative Care
- RARE: Rare Tumors
- RBTT: Randomized Brain Tumor Trials in Development
- RDNA: Radiation Biology and DNA Repair
- RTHP: Radiation Therapy
- STEM: Stem Cells
- SURG: Surgical Therapy
- TMIC: Tumor Microenvironment
- TMOD: Tumor Models

---

23rd Annual Scientific Meeting and Education Day Of The Society For Neuro-Oncology | 19
Sunrise Sessions


Mardi Gras F-H
Akitake Mukasa (Chair)

- WHO 2016 in Korea, Sung-Hye Park
- Implementation of molecular integrated diagnosis of adult gliomas in a resource-limited country, Takashi Komori
- Practical guidelines of implementing 2016 update in gliomas in the Asian context, Vani Santosh
- Integrated WHO 2016 diagnoses using immunohistochemistry, Arie Perry

Complexity of the Brain Tumor Microenvironment

Grand Ballroom Bissonet
Daniela Quail (Chair)

- Targeting macrophages in glioblastoma, Daniela Quail
- Effects of radiotherapy on brain metastasis-associated inflammation, Lisa Sevenich
- The role of the neural niche in brain metastasis, Josh Neman
- Lymphocytes in the glioma microenvironment, Amy Heimberger

Immune Based Therapies

Grand Ballroom Carondelet
Hideho Okada (Chair)

- Challenges for brain tumor immunotherapy, Hideho Okada
- Effects of systemic PD1 blockade therapy on the GBM tumor microenvironment, Robert Prins
- CAR therapy for GBM: Progress, promises and challenges, Behnam Badie
- Bone marrow T cell sequestration in GBM patients, Peter Fecci

Synthetic Lethal Strategies in Glioma: The Quest for Targetable Vulnerabilities

Galeries 1-2
Frank Furnari (Chair)

- Targeting cancer-specific vulnerabilities, Ronald DePinho
- Targeting a therapeutic vulnerability in PTEN-deficient brain tumor, Frank Furnari
- PARP inhibition: lessons learned from synthetic lethality, Clark Chen
- Targeting apoptotic pathway vulnerabilities in malignant glioma, David Nathanson

Update on Lower Grade Gliomas

Galeries 5-6
David Schiff (Chair)

- Classification and utility of biomarkers in lower-grade gliomas, David Capper
- Imaging advances in lower-grade gliomas, Raymond Huang
- Lessons from recent clinical trials of lower-grade gliomas, David Schiff
- Update on IDH-targeting strategies, Patrick Wen

Sex Differences in Brain Tumors: Biology and Therapeutic Implications

Mardi Gras A-B
Joshua Rubin (Chair)

- Sex specific differences in incidence, survival and risk factors for brain tumors, Jill Barnholtz-Sloan
- Sex differences in MR imaging of glioma, Kristin Swanson
- Sex differences in microglia and the glioma microenvironment, Justin Lathia
- Sex differences in glioma biology and therapeutic responses, Joshua Rubin

Brain Cancer Metabolism

Mardi Gras D-E
Paul Mischel (Chair)

- Co-dependency pathways in GBM: Identifying and targeting oncogene-induced metabolic vulnerabilities, Paul Mischel
- Monitoring metabolism in glioblastoma using hyperpolarized C-13 imaging and H-1 MRSI, Susan Chang
- Lipid metabolism alteration in GBM, from de novo synthesis to storage, Deliang Guo

Clonal Evolution of Adult and Pediatric Glioma

Grand Ballroom Acadia
Mario Suvê (Chair)

- An integrative model of cellular states and genetics for glioblastoma, Mario Suvê
- Functional characterization of tumor and non-tumor cells in glioblastoma, Antonio Iavarone
- DNA Amplification in cancer: It’s all about location, Kristen Turner
- K27M midline glioma: The “Peter Pan” syndrome, Nada Jabado
MAIN MEETING PROGRAM

9:00 - 9:05am  Welcome and Introduction of Scientific Program  
              Grand Ballroom  
              Frank Furnari, Daphne Haas-Kogan, Vinay Puduvalli

9:05 - 9:35am  Keynote Presentation: New cancer drugs aimed at oxygen sensing, cancer metabolism, and previously undruggable targets  
                William G. Kaelin Jr.

9:35 - 10:05am  Keynote Presentation: Pediatric clinical trials and translational research  
                 Maryam Fouladi

10:05 - 10:20am  BREAK  
                 Preservation Hall  
                 Wellness Pop Up: Body Relax. Visit the SNOCares booth 100-102.

10:20 - 10:55am  Victor Levin Award Introduction: Victor Levin

10:55 - 11:20am  Presidential Address: Patrick Wen

11:20 - 11:25am  SNO Membership Survey: Gelareh Zadeh

11:25 - 11:30am  SNO Convention Center Transition: Chas Haynes

11:30 - 11:40am  Preservation of neurocognitive function (NCF) with hippocampal avoidance during whole-brain radiotherapy (WBRT) for brain metastases: preliminary results of phase III trial NRG Oncology CC001  
                  APPLIED NEURO-ONCOLOGY AWARD  
                  Supported by the Sontag Foundation

11:40 - 12:00pm  Two-year results of the INTELLIGENCE EORTC trial 1410 randomized phase II study on Depatux–M alone, Depatux-M combined with temozolomide (TMZ) and either TMZ or lomustine in recurrent EGFR amplified glioblastoma (NCT02343406)  
                  ADULT CLINICAL RESEARCH AWARD  
                  Supported by the American Brain Tumor Association

11:50 - 12:00pm  The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune micro-environment of IDH-1-mutated gliomas via aryl hydrocarbon receptor signaling  
                  EANO TRAVEL GRANT AWARD

12:15 - 1:15pm  LUNCH  
                 Preservation Hall

LUNCHTIME TUTORIALS AND EDUCATIONAL SESSIONS

Not sponsored by The University of Texas MD Anderson Cancer Center

Palliative Care-Health Outcome Measures and Communication Strategies in Neuro-Oncology  
Mardi Gras A-B  
Zarnie Lwin (Chair)

- Prognostic understanding and communication challenges in patients with brain tumors, Deborah Forst
- Negotiating palliative care in the context of cultural and linguistic diversity – the role of the interpreter, Zarnie Lwin
- Advance care planning and palliative care in neuro-oncology, Tobias Walbert

Emerging Functional and Genomic Single Cell Technologies  
Mardi Gras D-E  
Paul Northcott (Chair)

- Single-cell genomics of medulloblastoma, Paul Northcott
- Developmental programs in H3K27M gliomas dissected by single cell RNAseq, Mariella Filbin
- Single-cell analysis of adult brain tumors, Aaron Diaz
12:15 - 1:15pm  LUNCH, continued

**Young Investigator Luncheon**  Riverview II
- Pre-grant preparation, Amy Heimberger
- Writing the grant, Eva Galanis
- The NIH perspective, Jane Fountain

**Epigenetics of CNS Malignancies**  Galeries 1-2
Anna Lasorella (Chair)
- Epigenetics in tumors of the central nervous system: an overview, Anna Lasorella
- DNA methylation-based classification of CNS tumors, Stefan Pfister
- Epigenetic changes in IDH1 mutant tumors, Houtan Noushmehr

**Emerging Model Systems in Neuro-Oncology**  Mardi Gras F-H
David Raleigh (Chair)
- Cilia-associated oxysterols activate smoothened in hedgehog pathway-associated medulloblastoma, David Raleigh
- The NCI Comparative Brain Tumor Consortium: Integration of canine patients into studies of CNS tumor biology and drug development, Amy LeBlanc
- Models of medulloblastoma for therapeutic discovery, Robert Wechsler-Reya

**Basic Science in Neuro-Oncology for the Clinician**  Galerie 3
Vinay Puduvalli (Chair)
- Basic mechanisms involved in tumor heterogeneity and treatment resistance, Vinay Puduvalli
- Translational strategies in neuro-oncology - from bench to bedside, Jann Sarkaria
- Immunological approaches against brain tumors, Duane Mitchell

**Industry Supported Symposium**  Galerie 5-6
Not sponsored by The University of Texas MD Anderson Cancer Center
- Integrative solutions to fragmented glioblastoma care in community and academic settings
  Sponsored by PRIME® through an education grant by AbbVie, Inc.

---

**CONCURRENT SESSIONS**  1:30 - 5:00 pm

1:30 - 3:00pm  CONCURRENT SESSION 2A

**Adult Clinical Trials I/Trials in Development**  Grand Ballroom Acadia - Bissonet
Moderators: Betty Kim, Jing Wu

**2A - GROUP 1**

1:30 - 1:40pm  ACTR-31
- Phase 1 study of AG-881, an inhibitor of mutant IDH1 and IDH2: results from the recurrent/progressive glioma population
  **ADULT CLINICAL RESEARCH AWARD**

1:40 - 1:50pm  ACTR-45
- Phase 0/2 study of ribociclib in patients with recurrent glioblastoma

1:50 - 1:55pm  ACTR-13
- A bayesian adaptive randomized phase II trial of bevacizumab versus bevacizumab plus vorinostat in adults with recurrent glioblastoma – final results

1:55 - 2:00pm  RARE-24
- Objective response and clinical benefit in recurrent ependymoma in adults: final report of CERN 08-02: A phase II study of dose-dense temozolomide and lapatinib

2:00 - 2:05pm  DISCUSSANT  Susan Chang

2:05 - 2:10pm  2A - Audience Q&A (GROUP 1)

**2A - GROUP 2**

2:10 - 2:15pm  ACTR-02
2:15 - 2:20pm
ACTR-61
Long-term analyses of the NOA-08 randomized phase III trial

2:20 - 2:25pm
ACTR-38
A phase I trial of afatinib and radiotherapy (RT) with or without temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM)

2:25 - 2:30pm
ACTR-30
Phase 1b/2 study to assess the clinical effects of paminiparib (BGB-290) in combination with radiation therapy (RT) and/or temozolomide (TMZ) in patients with newly diagnosed or recurrent/refractory glioblastoma (GBM)

2:30 - 2:35pm
2A - Audience Q&A (GROUP 2)

2:35 - 2:40pm
ACTR-67
A phase I study of convection-enhanced delivery of liposomal-irinotecan (Onivyde) using real-time imaging with gadolinium in patients with recurrent high grade gliomas: results thus far

2:40 - 2:45pm
ACTR-33
Tumor tissue penetration and pharmacodynamics of ONC201 in adult recurrent glioblastoma patients

2:45 - 2:50pm
ACTR-16
Peripheral blood CD4+ mononuclear cell fractions are associated with overall survival at first recurrence of IDH-wildtype glioblastoma after standard chemoradiotherapy: secondary analyses of the phase II DIRECTOR trial

2:50 - 2:55pm
ACTR-29
Peripheral blood CD4+ mononuclear cell fractions are associated with overall survival at first recurrence of IDH-wildtype glioblastoma after standard chemoradiotherapy: secondary analyses of the phase II DIRECTOR trial

2:55 - 3:00pm
2A - Audience Q & A (GROUP 3)

3:00 - 3:15pm
BREAK Preservation Hall

1:30 - 3:00pm
CONCURRENT SESSION 2B

Practical and Applied Neuro-Oncology I Grand Ballroom Carondelet
Moderators: Melissa Bondy, Kyle Noll
2B - GROUP 1

1:30 - 1:40pm
QOLP-30
Survival, local control, and health related quality of life in oligometastatic and polymetastatic spinal tumors: multicenter, international study

1:40 - 1:50pm
QOLP-20
Quality of life in the phase III CeTeG/NOA-09 trial randomizing CCNU/temozolomide (TMZ) combination therapy vs. standard TMZ therapy for newly diagnosed MGMT-methylated glioblastoma

1:50 - 2:00pm
HOUT-19
Treatment patterns, outcomes, and prognostic indicators in elderly patients with glioblastoma: a retrospective single institution analysis

2:00 - 2:05pm
DISCUSSANT Martin Taphoorn

2:05 - 2:10pm
QOLP-12
A novel multidisciplinary care clinic model for frail patients with central nervous system malignancies
2:15 - 2:20pm  
End of life phase in glioblastoma: prospective assessment of symptom burden and symptom interference in the end of life phase - final analysis  
Walbert T, Schultz L

2:20 - 2:25pm  
Symptom clusters in newly diagnosed glioma patients: which clusters are associated with functioning and global health status?  

2:25 - 2:30pm  
The relationship between caregiving burden and anxiety symptoms in caregivers of patients with malignant gliomas  
Quain K, Nipp R, Greer J, El-Jawahri A, Batchelor T, Temel J, Forst D

2:30 - 2:35pm  
2B - Audience Q&A (GROUP 2)  
2B - GROUP 3

2:35 - 2:40pm  
Effect of intensive nutrition intervention on pediatric patients with central nervous system tumors with concurrent radiochemotherapy  
Cai LB, Zhang Y

2:40 - 2:45pm  
Association between body image investment and alteration in patients with primary brain tumors  

2:45 - 2:50pm  
Isocitrate dehydrogenase mutations and increased tissue 2-hydroxyglutarate concentration might be related with seizure onset in patients with gliomas  
Ohno M, Hayashi M, Matsushita Y, Miyakita Y, Takahashi M, Yamazawa E, Tsushita N, Ichimura K, Hamada A, Narita Y

2:50 - 2:55pm  
Effects of proton radiation on brain structure and function in low grade glioma  

3:00 - 3:15pm  
BREAK  
Preservation Hall

1:30 - 3:00pm  
CONCURRENT SESSION 2C

Experimental Therapeutics  
Mardi Gras D-E  
Moderators: Milan Chheda, Katherine Warren

2C - GROUP 1

1:30 - 1:40pm  
Bifunctional RNA nanoparticles induce antitumor immune responses and allow MRI-based detection of dendritic cell migration as a biomarker of antitumor immune response  

1:40 - 1:50pm  
Inflammatory reprogramming of gliomas using Delta-24-RGDOX and immunomodulatory adjuvants  

1:50 - 2:00pm  
Dianhydrogalactitol (VAL-083) reduces glioblastoma tumor growth in vivo, upon bevacizumab-induced hypoxia  
Golebiewska A, Oudin A, Steino A, Nicolou S, Brown D, Bacha J

2:00 - 2:10pm  
Local oncolytic adenovirus treatment affects both the innate and adaptive arms of the immune system and provides an avenue for enhancing immunotherapies for GBM  

2:10 - 2:15pm  
DISCUSSANT  
W.K. Alfred Yung

2:15 - 2:20pm  
2C - Audience Q&A (GROUP 1)

2:20 - 2:25pm  
Efficient delivery of siRNAs to glioma via functionalized extracellular vesicles primed by radiation  
Tannous B, Tian T, Obeid P

2:25 - 2:30pm  
Effective treatment of canine spontaneous gliomas with a cytotoxic cocktail targeting IL-13RA2 and EphA2 receptors  
Rossmeisl J, Herpai D, Robertson J, Dickinson P, Tatter S, Debinski W
## 2:30 - 2:35pm
**Transgenic expression of IL15 improves the efficacy of CAR T cells in an immune competent glioblastoma model**  

## 2:35 - 2:40pm
**2C - Audience Q&A (GROUP 2)**

## 2:40 - 2:45pm
**G-quadruplex DNA drives genomic instability and represents a targetable molecular abnormality in ATRX-deficient malignant glioma**  
*Wang Y, Yang J, Danussi C, Riggins G, Sulman E, Chan T, Huse JT*

## 2:45 - 2:50pm
**A novel nanotechnology-based platform improves laser interstitial thermal therapy for intracranial tumors**  

## 2:50 - 2:55pm
**Targeting CD97 by novel fusion protein DAF-Fc inhibits GBM invasion and induces antibody dependent cellular cytotoxicity**  
*Nguyen A, Safaee M, Chandra A, Wycoff K, Aghi M*

## 2:55 - 3:00pm
**2C - Audience Q&A (GROUP 3)**

## 3:00 - 3:15pm
**BREAK**  
*Preservation Hall*

## 3:15 - 5:00pm
### 3A - GROUP 1

#### 3A - GROUP 1

#### 3:15 - 3:25pm
**Optical barcoding to investigate clonal dynamics of GBM highlights the intrinsic capacity of GBM to re-activate developmental genes and escape immune surveillance**  

#### 3:25 - 3:35pm
**Neoadjuvant anti-PD-1 immunotherapy promotes intratumoral and systemic immune responses in recurrent glioblastoma: An Ivy Consortium trial**  

#### 3:35 - 3:45pm
**Results of the GLOBE study: a phase 3, randomized, controlled, double-arm, open-label, multi-center study of VB-111 combined with bevacizumab vs. bevacizumab monotherapy in patients with recurrent glioblastoma**  
*Cloughesy T, Brenner AJ, Butowski N, Cohen YC, Lowentan-Spieer N, Wen P*

#### 3:45 - 3:55pm
**Phase II trial of a survivin vaccine (SurVaxM) for newly diagnosed glioblastoma**  

#### 3:55 - 4:00pm
**DISCUSSANT Sourav Ghosh**

#### 4:00 - 4:05pm
**3A - Audience Q&A (GROUP 1)**

#### 4:05 - 4:10pm
**Dose modulation of temozolomide have distinct effects on host response to PD-1 blockade**  

#### 4:10 - 4:15pm
**Retargeting immunoedited glioma escape variants with adoptive cellular therapy**  
*Wildes T, Dyson K, Grippin A, DiVita B, Flores C, Mitchell D*

#### 4:15 - 4:20pm
**Absence of the amino acid stress-sensor GCN2 reduces suppressive effects of MDSCs in glioma**  

#### 4:20 - 4:25pm
**Neoadjuvant PD-1 antibody blockade is associated with focal upregulation of PD-L1 and CD8 T cell infiltrate in recurrent glioblastoma**  
*Orpilla J, Mochizuki A, Reynoso J, Akkad N, Lee A, Davidson T, Liou L, Cloughesy T, Prins R*

#### 4:25 - 4:30pm
**Phase 2 trial of SL-701 + bevacizumab in patients with previously treated glioblastoma (GBM) meets primary endpoint of OS-12, with preliminary correlation between long-term survival and target-specific CDB8+ T cell immune response**  

#### 4:30 - 4:35pm
**3A - Audience Q&A (GROUP 2)**
3A - GROUP 3

4:35 - 4:40pm
**ATIM-17**

Pembrolizumab blocks PD-1 on CAR T cells administered intraventricularly to glioblastoma patients


4:40 - 4:45pm
**IMMU-55**

Immunomodulatory IL-7 and IL-12-expressing MSCs induce long-term survival and immunity in syngeneic intracerebral glioblastoma models


4:45 - 4:50pm
**IMMU-58**

Reduced neoantigen expression as a possible immune evasion mechanism during glioma progression


4:50 - 4:55pm
**IMMU-28**

High-dimensional single cell characterization of the systemic influence of neoadjuvant PD-1 blockade in patients with recurrent glioblastoma


4:55 - 5:00pm
**3A - Audience Q&A (GROUP 3)**

---

3:15 - 5:00pm
**CONCURRENT SESSION 3B**

Genetics/Epigenetics/Computational Omics  Grand Ballroom Carondelet

Moderators: Mariella Filbin, Kerrie McDonald

3B - GROUP 1

3:15 - 3:25pm
**GENE-42**

The genomic landscape of triple-negative glioblastoma


3:25 - 3:35pm
**COMP-07**

Comparative molecular life history of spontaneous canine and human glioma


3:35 - 3:45pm
**GENE-18**

Divergent clonal evolution of melanoma brain metastases during treatment with immunotherapy


3:45 - 3:50pm
**DISCUSSANT** Pratiti Bandopadhayay

3:50 - 3:55pm
**3B - Audience Q&A (GROUP 1)**

3B - GROUP 2

3:55 - 4:00pm
**GENE-35**

IDH1-R132H induces an epigenetic reprogramming in glioma impacting median survival, DNA-damage response and radio-sensitivity


4:00 - 4:05pm
**GENE-22**

Re-programing chromatin with a bifunctional LSD1/HDAC inhibitor induces therapeutic differentiation in DIPG


4:05 - 4:10pm
**COMP-20**

The non-invasive detection of glioblastoma-derived cell-free DNA in plasma using next-generation sequencing and an untargeted variant search

*Underhill H, Hellwig S, Nix D, Bhetariya P, Fuertes C, Marth G, Colman H, Bronner M, Jensen R*

4:10 - 4:15pm
**COMP-06**

Glioblastoma development mirrors the developing brain


4:15 - 4:20pm
**3B - Audience Q&A (GROUP 2)**

3B - GROUP 3

4:20 - 4:25pm
**GENE-06**

The oncohistone H3.3K27M drives diffuse intrinsic pontine glioma independent of functional EZH2

*Dhar S, Becher O*

4:25 - 4:30pm
**GENE-34**

Mouse model of diffuse intrinsic pontine glioma harboring Acvr1 G328V

*Mendez F, Nunez F, Koschmann C, Ravindran R, Dziaman M, Lowenstein P, Castro M*
4:30 - 4:35pm Molecular characterization of benign and malignant peripheral nerve sheath tumors that occur in sporadic and syndromic settings

4:35 - 4:40pm 3B - Audience Q&A (GROUP 3)

4:40 - 4:45pm Functional genomic elements defined by DNA methylation can distinguish meningioma subgroups

4:45 - 4:50pm Tumor evolution directed graphs imply therapies against moving targets in pan-gliomas
Wana J

4:50 - 4:55pm Intron 1-mediated regulation of EGFR expression in EGFR-dependent malignancies
Jameson N, Tang J, Parisian A, Benitez J, Furnari F

4:55 - 5:00pm 3B - Audience Q&A (GROUP 4)

3:15 - 5:00pm CONCURRENT SESSION 3C

Microenvironment/Angiogenesis and Invasion  Mardi Gras D-E
Moderators: Biplab DasGupta, Candelaria Gomez-Manzano

3C - GROUP 1

3:15 - 3:25pm Abscopal immune response in glioblastoma elicited by miR124-attenuated oncolytic herpes simplex virus 1 armed with UL16 binding protein 3

3:25 - 3:35pm Core-like tumor cells promote malignance of glioblastoma via intercellular cross-talk with edge-like tumor cells in a HDAC1-CD109 dependent manner

3:35 - 3:45pm Reprogramming bone marrow of tumor-bearing hosts for glioma immunotherapy
Wildes T, DiVita B, Grippin A, Dyson K, Flores C, Mitchell D

3:45 - 3:55pm Epigenetic reactivation of BAI1 suppresses tumor invasion by preventing TGFβ1-induced mesenchymal switch in glioblastoma
Osuka S, Yang L, Zhu D, Devi N, Van Meir E

3:55 - 4:00pm DISCUSSANT  Michael Berens

4:00 - 4:05pm 3C - Audience Q&A (GROUP 1)

3C - GROUP 2

4:05 - 4:10pm 5ALA fluorescence based sorting identifies SERPINE1 as a novel therapeutic target on invasive GBM cells
Rowlinson J, de los Angeles Estevez Cebrero M, Lourdusamy A, Rahman R, Smith S

4:10 - 4:15pm Fibroblast-produced EDA fibronectin in the subventricular zone drives glioblastoma pathogenesis

4:15 - 4:20pm Glioblastoma exploits cell surface glycosylation-mediated immune regulatory circuits for immune escape

4:20 - 4:25pm PDGF-mediated mesenchymal transformation renders endothelial resistance to anti-VEGF treatment in glioblastoma
Ma W, Gong Y, Brem S, Fan Y

4:25 - 4:30pm Activation of the Wnt/β-Catenin signaling pathway in glioma stem cells impacts endothelial cell-cell interaction
Vézina A, Gilbert M, Jackson S

4:30 - 4:35pm 3C - Audience Q&A (GROUP 2)

3C - GROUP 3

4:35 - 4:40pm Interleukin-6 in cerebrospinal fluid as a prognostic marker for glioblastoma patients
4:40 - 4:45pm Na/H exchanger isoform 1 (NHE1) in immunosuppressive tumor microenvironment in mouse syngeneic glioma model
Hasan N, Guan X, Kohanbash G, Sun D

4:45 - 4:50pm Computational characterization of suppressive immune microenvironments in glioblastoma

4:50 - 4:55pm Genetic driver-mutations define composition and properties of tumor-associated myeloid cells in glioblastoma
Chen Z, Murukuti J, Hambardzumyan D

4:55 - 5:00pm 3C - Audience Q&A (GROUP 3)

5:00 - 7:00pm Factors Impacting Clinical Trial Accrual - A SNO/RANO Initiative
Grand Ballroom Acadia - Bissonet
Chairs: Patrick Wen, Eudocia Quant Lee, Terri Armstrong, David Arons

5:00 - 5:30pm Refreshments

5:30 - 5:35pm Introduction
Patrick Wen

5:35 - 5:43pm National Brain Tumor Society survey results
David Arons

5:43 - 5:51pm SNO clinical trials survey
Terri Armstrong

5:51 - 6:01pm Patient and community factors
John DeGroot, David Arons

6:01 - 6:11pm Physician and provider factors
Susan Chang

6:11 - 6:21pm Clinical trials factors
David Reardon

6:21 - 6:31pm Site and organizational factors
Michael Weller

6:31 - 6:41pm Disparities
Ugonma Chukwueke, Shawn Hervey-Jumper

6:41 - 6:51pm Future directions
Eudocia Quant Lee, Patrick Wen

6:51 - 7:00pm Discussion and wrap-up

5:30 - 7:30pm Industry Supported Symposia
Not sponsored by The University of Texas MD Anderson Cancer Center

- The role of the neuro-oncologist in EGFR-Mutant NSCLC: treating leptomeningeal carcinomatosis with the multidisciplinary team
  Supported by priME Oncology through an education grant by AstraZeneca
- Novalis circle symposium: technological advances in the treatment of intracranial metastasis
  Supported by Brainlab

7:30 - 9:30pm E-TALKS Interactive Electronic 4 Minute Presentations Followed By Traditional Poster Viewing and Discussions
Sheraton Hotel - Grand Ballroom

Group 1: Cell Signaling/Cell Biology/Metabolism/Genetics/Epigenetics
Group 2: Drug Resistance/Drug Discovery/Experimental Therapeutics/Tumor Microenvironment
Group 3: Imaging/Pediatric Tumor Models/Pediatric Clinical Trials/Molecular Pathology/Health Outcomes

7:30 - 9:30pm POSTER SESSION Traditional Poster Viewing
Sheraton Hotel - Grand Ballroom
E-TALKS  7:30 - 9:30pm

GROUP 1: Cell Signaling/Cell Biology/Metabolism/Genetics/Epigenetics

Moderators: Erica Bell, Kyle Walsh

7:30 - 7:34pm
GENE-13
Genomic functional enhancers define potential tumorigenesis of G-CIMP-low (IDH-mutant Astrocytoma) tumors independent of promoter methylation
Sabedot T, deCarvalho A, Poisson L, Snyder J, Walbert T, Lee I, Kalkanis S, Berman B, Noushmehr H

7:34 - 7:38pm
GENE-28
Methylomes and transcriptomes vary across IDH1 mutant cancers
Scholtens D, Zewe M, Buss A, James D, Unruh D, Horbinski C

7:38 - 7:42pm
COMP-24
Utilizing machine learning methods for segmentation and classification of brain tumors based on conventional MRI
Artzi M, Bressler I, Bashat DB

7:42 - 7:46pm
CSIG-42
High throughput kinome and transcriptome analyses reveal novel therapeutic targets in NF2-deficient meningioma

7:46 - 7:50pm
CSIG-25
Epidermal Growth Factor Receptor extracellular domain missense mutation A289V as a driver of glioblastoma invasion and proliferation

7:50 - 7:54pm
CSIG-47
TRIM24 is an oncogenic transcriptional co-activator of STAT3 in glioblastoma
Feng H

7:54 - 7:58pm
CSIG-06
The molecular subtype of Primary Glioblastoma cells correlates with response to therapeutic agents that induce apoptosis or senescence.
Kumar R, Lorimer I

7:58 - 8:02pm
CSIG-43
The tyrosine phosphatase PTPN12/PTP-PEST regulates phosphorylation-dependent ubiquitination and stability of focal adhesion substrates in Invasive glioblastoma cells
McCarty J, Morales J, Guerrero P, Chen Z

8:02 - 8:06pm
CBMT-35
MicroRNA analysis of the invasive margin of glioblastoma reveals druggable therapeutic targets in lipid metabolism pathways

8:06 - 8:10pm
CBMT-10
Glutamine deprivation alters one-carbon metabolism to maintain glioma cell survival
Tanaka K, Sasayama T, Uno T, Maeyama M, Fujita Y, Irino Y, Kohmura E

8:10 - 8:14pm
CBMT-41
Glioblastoma clones derived from tumor core and edge display spatial metabolic heterogeneity

8:14 - 8:18pm
CBMT-39
Metabolic profiling of human gliomas assessed with NMR
Yang S-H, Eun Lee J

8:18 - 8:22pm
CBMT-23
Modulation of hypersynaptic microenvironment differentially promotes gliomagenesis across PIK3CA variants
7:30 - 7:34pm  EGFR-targeted therapy-induced resistance mechanism in malignant gliomas  

7:34 - 7:38pm  Proteasome inhibition is a targeted therapy for PTEN-deficient glioblastomas  
Benitez J, Finlay D, Ma J, Koga T, Vuori K, Fumari F

7:38 - 7:42pm  CT-179: an inhibitor of the OLG2 transcription factor with potent anti-tumour activity in brain cancer  

7:42 - 7:46pm  Compounds identified by structure based virtual screening decrease GBM BTIC growth and glucose uptake  

7:46 - 7:50pm  Targeting glioblastoma heterogeneity with miR-34a  
Khan M, Ruggieri R, Tran N, Sarkaria J, MacDiarmid J, Brahmbhatt H, Boockvar J, Symons M

7:50 - 7:54pm  Use of a phospholipid binding MARCKS mimetic for targeted killing of glioblastoma cells  

7:54 - 7:58pm  Impaired PARP1 DNA repair defines chemo-sensitivity in IDH1-mutated cells  

7:58 - 8:02pm  In vivo quantitative analysis of oncolytic virus-tumor kinetics  
Ito H, Nakashima H, McLaughlin E, Chiocca EA

8:02 - 8:06pm  Selective, non-competitive DRD2/3 antagonism by imipridone ONC206 is effective in tumors with dopamine receptor dysregulation  

8:06 - 8:10pm  Imipridones cause metabolic reprogramming and elicit unique vulnerabilities in preclinical model systems of glioblastoma  

8:10 - 8:14pm  Auto-/paracrine signaling of PI3K/AKT/YKL-40 in mesenchymal glioblastoma progression  

8:14 - 8:18pm  Tumor-suppressive and anti-inflammatory microRNA-93 is decreased in glioblastoma patients  
Hübner M, Effinger D, Hinske C, Möllhoff N, Kreth F-W, Kreth S

8:18 - 8:22pm  OMX is a tumor microenvironment modifier that restores anti-tumor immunity and improves anti-tumor efficacy by reducing tumor hypoxia in intracranial glioblastoma mouse model  
Le Moan N, Davis T, Leung P, Ng S, Winger J, Cary S, Butowski N, Krtolica A

8:22 - 8:26pm  Dissecting the role of host genetics in glioma evolution using genetically-engineered mouse models and the Collaborative Cross  

8:26 - 8:30pm  Nonfunctional pituitary adenomas demonstrate two subtypes based on macro-phage polarization status  
Yagink G, Rutkowski M, Aghi M
7:30 - 7:34pm  
**NIMG-22**  
High-grade glioma outcomes in the Phase 1 BXQ-350 trial of cancer-selective SapC-DOPS nanovesicles  

7:34 - 7:38pm  
**NIMG-06**  
Kinetics-based response metric discriminate improved outcomes for patients receiving bevacizumab-based therapies  

7:38 - 7:42pm  
**PDTM-24**  
Pilot study of circulating tumor cells in pediatric high grade brain tumors  

7:42 - 7:46pm  
**PDTM-37**  
The role of exosome miRNA during the progression of medulloblastoma  
*Chang Q, Zhu L-Y, Wu X-U, Zhang J*

7:46 - 7:50pm  
**PDTM-05**  
Radiation DNA damage repair inhibition by GSK-J4 induced chromatin compaction in DIPG  

7:50 - 7:54pm  
**PDTM-29**  
CSF H3F3A K27M circulating tumor DNA copy number quantifies tumor growth and treatment response  

7:54 - 7:58pm  
**PDTM-46**  
Poliovirus receptor (CD155) expression in pediatric brain tumors mediates oncolysis of medulloblastoma and pleomorphic xanthoastrocytoma  

7:58 - 8:02pm  
**PDTM-47**  
Real time in vivo monitoring of 18F-labeled panobinostat pharmacokinetics for treatment of diffuse intrinsic pontine glioma (DIPG) via convection enhanced delivery (CED).  
*Tosi U, Kommidil H, Bhanu Maachani U, Marnell C, Guo H, Schweitzer M, Ting R, Souweidane M*

8:02 - 8:06pm  
**PATH-42**  
EGFR-amplified IDH-wildtype glioblastomas seldom transform into a hypermutated phenotype  

8:06 - 8:10am  
**PATH-25**  
Survival stratification of IDH mutant glioma using methylation and mRNA analysis of Hox genes  

8:10 - 8:14am  
**PATH-31**  
Giant cell glioblastomas: analysis of mismatch-repair (MMR) proteins expression, Polymerase ε (POLE) mutations and their role in tumor immunoresponse  
*Pollo B, Patanè M, Calatozzolo C, Paterra R, Farinotti M, Spinello S, DiMece F, Silvani A, Finocchiaro G*

8:14 - 8:18am  
**PATH-16**  
Molecular pathology and clinical characteristics of MMR deficiency (MM Rd) in diffuse gliomas  

8:18 - 8:22pm  
**NCOG-09**  
The level of reporting of neurocognitive outcomes in randomized controlled trials of brain tumor patients: a systematic review  
*Habets E, Taphoorn M, Klein M, Vissers T, Dirven L*

8:22 - 8:26am  
**PDCT-06**  
Phase 1 study of ONC201 in pediatric patients with H3 K27M-mutant high grade glioma or newly diagnosed DIPG  

8:26 - 8:30am  
**PDCT-08**  
Tracking the T cell repertoire after adoptive cell therapy in pediatric patients with recurrent medulloblastoma  
*Yegorov O, Yegorova Y, Dechkovskia A, Cleaver B, Clement N, Slayton W, Gururangan S, Mitchell D*

8:30 - 9:30am  
E-talk presenters move to their designated posters in the general poster session for further discussion
SUNRISE SESSIONS  7:00 - 8:30am

EANO/SNO: Status Update: What failed, what remains, what is new?  Galeries 5-6
Martin van den Bent, Patrick Wen (Chairs)
- WHO classification interpreted by cIMPACT NOW, Kenneth Aldape
- IDH biology, Sevin Turcan
- Tackling heterogeneity, Monika Hegi
- Immunotherapy 2018, Amy Heimberger
- Precision concepts for daily practice and trials, Wolfgang Wick

Diffuse Intrinsic Pontine Glioma - New Insights and Emerging Therapeutic Strategies  Galeries 1-2
Michelle Monje-Deisseroth (Chair)
- Targeting microenvironmental dependencies of DIPG, Michelle Monje-Deisseroth
- Harnessing exquisite vulnerabilities in H3K27M mutagenesis, Nada Jabado
- Developmental programs in H3K27M gliomas dissected by single cell RNAseq, Mariella Filbin
- Targeting histone-3 variant H3.3K27M mutation for immunotherapy of diffuse midline glioma, Hideho Okada

Brain Metastases Biology  Grand Ballroom Acadia
Frank Winkler (Chair)
- Brain metastases biology: from seed to soil, Frank Winkler
- Genetic evolution in brain metastases, Priscilla Brastianos
- Microenvironmental dynamics in leptomeningeal metastasis, Adrienne Boire
- Immunotherapy for brain metastases, Mihaela Lorger

Neurotoxicity of CAR T Therapy (AAN/SNO)  Mardi Gras D-E
Jorg Dietrich (Chair)
- Clinical patterns of neurotoxicity associated with immunotherapies, Jorg Dietrich
- Mechanisms of CAR-T cell mediated toxicities, Verena Staedtke
- EEG findings after CAR-T cell therapy, Aline Herlopian
- Clinical spectrum of CAR-T cell associated neurotoxicity, Bianca D. Santomasso

Targeted Therapies in Neurofibromatosis  Grand Ballroom Bissonet
Scott Plotkin (Chair)
- Clinical trials of MEK inhibitors for pediatric and adult NF1 patients with progressive plexiform neurofibroma, Jaishri Blakeley
- Activity and safety of cabozantinib for treatment of progressive plexiform neurofibroma in NF1 patients, Chie-Schin Shih
- Recent data from trials of targeted therapies to treat NF1-related low grade gliomas, Jason Fangusaro
- Activity and safety of bevacizumab for treatment of progressive vestibular in NF2 patients, Scott Plotkin

Molecular Life History of Glioma  Grand Ballroom Carondelet
Roel Verhaak (Chair)
- Molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis consortium, Roel Verhaak
- Single-cell strategies for defining clonal hierarchies in pediatric and adult brain tumors, Peter Dirks
- The nursery of childhood gliomas, Stefan Pfister
- Complex re-arrangements in pediatric brain tumors, Jinghui Zhang

Patient Centered Outcomes and Net Clinical Benefit in Brain Tumor Clinical Trials  Mardi Gras F-H
Jeffrey Wefel (Chair)
- Has adding tests of neurocognitive function to clinical trials in patients with brain tumor had an impact on patient care? Jeffrey Wefel
- Has adding patient reported outcomes to clinical trials in patients with brain tumor had an impact on patient care? Terri Armstrong
- ESMO-Magnitude of Clinical Benefit Scale - is it applicable for glioma clinical trials? Leor Zach
- How does the 21st Century Cures Act influence the use of patient centered outcomes in the drug approval process? Joohee Sul

Radiation Therapy of GBM in the Era of Personalized Medicine  Mardi Gras A-B
Daphne Haas-Kogan (Chair)
- Emerging opportunities to chemo/radio-sensitize IDH1/2-mutant glioma, stories from the bench-to-the-bedside, Ranjit Bindra
- Radiation therapy of GBM in the era of personalized medicine, Fen Xia
- Exploiting nuclear envelope fragility as a radiosensitizing strategy in gliomas, Alexander Spektor
- Overcoming radiation resistance in patients with glioblastoma: is more better? Erik Sulman
# MAIN MEETING PROGRAM

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:00 - 9:05am</td>
<td><strong>Welcome/In Memoriam</strong>&lt;br&gt;Daphne Haas-Kogan</td>
<td>Grand Ballroom Acadia - Bissonet - Carondelet</td>
</tr>
<tr>
<td>9:05 - 9:35am</td>
<td><strong>Keynote Presentation:</strong> Considerations for clinical development in glioma&lt;br&gt;Timothy Cloughesy</td>
<td></td>
</tr>
<tr>
<td>9:35 - 10:05am</td>
<td><strong>Keynote Presentation:</strong> Challenges for immunotherapy against brain tumors&lt;br&gt;John H Sampson</td>
<td></td>
</tr>
<tr>
<td>10:05 - 10:20am</td>
<td><strong>BREAK</strong>&lt;br&gt;Wellness Pop Up: Time Management. Visit the SNOCares booth 100-102.</td>
<td>Preservation Hall</td>
</tr>
<tr>
<td>10:20 - 10:50am</td>
<td><strong>Abhijit Guha Award Introduction:</strong> Gelareh Zadeh&lt;br&gt;Abhijit Guha Lecture Award Recipient: Brain tumor immunotherapy: lessons learned and future directions, Linda Liau</td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:00am</td>
<td><strong>Lifetime Achievement Award Introduction:</strong> Warren Mason&lt;br&gt;Lifetime Achievement Award Recipient: Gregory Cairncross</td>
<td></td>
</tr>
<tr>
<td>11:00 - 11:10am</td>
<td><strong>Neuro-Oncology Community Service Award Introduction:</strong> Patrick Wen&lt;br&gt;Neuro-Oncology Community Service Award Recipient: David Arons</td>
<td></td>
</tr>
<tr>
<td>11:10 - 11:20am</td>
<td><strong>Jan Esenwein Public Service Award Introduction:</strong> Susan Chang&lt;br&gt;Jan Esenwein Public Service Award Recipient: Chas Haynes</td>
<td></td>
</tr>
<tr>
<td>11:20 - 11:30am</td>
<td><strong>Single-cell level comparison of histopathology and single-cell RNA-seq databases between IDH-MUT and –WT glioblastomas reveals distinct innate immune microenvironments that can be exploited for therapeutic gain</strong>&lt;br&gt;<strong>IMMU-40</strong>&lt;br&gt;Poon CC, Liu K, Gordon P, Yang R, Sarkar S, Mirzaei R, Sheikh T, Huges M, Yong W, Kelly J</td>
<td></td>
</tr>
<tr>
<td>12:15 - 1:15pm</td>
<td><strong>LUNCH</strong>&lt;br&gt;Preservation Hall</td>
<td></td>
</tr>
</tbody>
</table>

## LUNCHTIME TUTORIALS AND EDUCATIONAL SESSIONS

Not sponsored by The University of Texas MD Anderson Cancer Center

**Current State of Glioma Epidemiology and Moving the Science Into the Future**<br>Galerie 3<br>**Melissa Bondy** (Chair)
- Overview of the current state of epidemiology research, **Melissa Bondy**
- Novel approaches to patient recruitment and clinical intervention using social media and smart phone technology, **Elizabeth Claus**
- Leveraging big data to impact brain tumor research, **Jill Barnholtz-Sloan**

**International Outreach Luncheon**<br>Galerie 4<br>**Jason Huse, Mustafa Khasraw** (Chairs)
- SNO Wilkins-Barrick Neuro-Oncology Course, Peru 2018 Report, **Rosdali Diaz Coronado**
- SNO Sub-Saharan Africa Conference, Nigeria 2018 Report, **James Balogun, Edjah Nduom**
- Introduction of Travel Scholarship Recipients and Poster Presentations
### Main Meeting Saturday, November 17

**12:15 - 1:15pm  LUNCH, continued**

**Computational Neuro-Oncology  Galeries 1-2**

- Spyridon Bakas (Chair)
- The role of computational biology in the current WHO classification of CNS tumors, Roel Verhaak
- Computational diagnostics of CNS tumors in the era of radiomics and radiogenomics, Christos Davatzikos
- Computational modeling of tumor growth, invasion and proliferation, Kristin Swanson

**Surgical Trials: From Design to Regulatory Approval  Mardi Gras D-E**

- Linda Liau (Chair)
- Cellular immunotherapy approaches for brain tumors, Linda Liau
- Oncolytic virotherapy for brain tumors, James Markert
- Drug delivery approaches for brain tumors, Russell Lonser

**Novel Statistical Designs and Methods for Neuro-Oncology Clinical Trials  Mardi Gras F-H**

- Ying Yuan (Chair)
- Designs for small patient populations, Karla Ballman
- Biomarker-based and basket trials in neuro-oncology, Annette Molinaro
- Novel designs for phase I neuro-oncology trials, Ying Yuan

**Meet the Editors  Mardi Gras A-B**

- Patrick Wen (Chair)
- Introduction, Patrick Wen
- Neuro-Oncology Practice update, Susan Chang
- Neuro-Oncology update, Kenneth Aldape
- Journal of Neuro-Oncology update, Linda Liau

**Neuro-Oncology Trainee Forum  Balcony J**

- Neuro-Oncology career search - avoiding pitfalls and gauging the needs against what programs have to offer, Vinay Puduvalli
- Contract negotiation - pitfalls and opportunities, Nina Paleologos
- Working for the FDA as a neuro-oncologist, Joohee Sul

**Industry Supported Symposium  Galeries 5-6**

- Not sponsored by The University of Texas MD Anderson Cancer Center
- Transforming glioblastoma management - a MasterClass on evaluating newer and emerging options in the precision medicine and person-centered care era
  
  Jointly provided by PVI, PeerView Institute for Medical Education and Medical Learning Institute, Inc., supported by an educational grant from Novocure, and developed in collaboration with the American Brain Tumor Association

### 1:30 - 3:00pm  Concurrent Session 5A

**Metabolomics/Cell Biology/Cell Signaling  Grand Ballroom Acadia - Bissonet**

**5A - GROUP 1**

**1:30 - 1:40pm CBMT-37**

- FDA-approved HDAC inhibitors antagonize the Warburg effect and cause unique metabolic vulnerabilities
  - Zhang Y, Ishida C, Karpel-Massler G, Siegelin M

**1:40 - 1:50pm CBMT-15**

- Metabolic and transcriptional profiles of GBM invasion: Comparison of patients and paired patient derived xenografts using $^1$H Magnetic Resonance Spectroscopy and Imaging (7T and 14T) and RNA-sequencing

**1:50 - 2:00pm CBMT-22**

- The PI3K/mTOR pathway contributes to sex differences in glioblastoma
  - Sponagel J, Yu K, Deneen B, Ippolito J, Rubin J

**2:00 - 2:10pm CBMT-04**

- Inducing mitochondrial oxidative stress and targeting cellular stress response by inhibition of NAMPT, the rate limiting enzyme in the NAD+ salvage pathway in glioma
  - Sharma I, Senepides W, Bologlu E, Puduvalli V

**2:10 - 2:15pm**

- DISCUSSANT  Shiyuan Cheng

**2:15 - 2:20pm 5A - Audience Q&A (GROUP 1)**

**5A - GROUP 2**

**2:20 - 2:25pm CSIG-40**

- Heterozygous IDH1 R132H/WT created by “single base editing” inhibits human astroglial cell growth and promotes cell migration
  - Wei S, Wang J, Oyinade O, Ma D, Wang S, Qian, J, Xia S
2:25 - 2:30pm CSIG-37
FOXr2 stabilizes MYC and activates FAK/SRC signaling in a dual mechanism to promote transformation in neural progenitor cells
*Beckmann P, Larson J, Larsson A, Ostergaard J, Largaespada D*

2:30 - 2:35pm CBMT-32
Imaging a hallmark of cancer: TERT expression leads to MRS-detectable metabolic reprogramming
*Viswanath P, Pieper R, Ronen S*

2:35 - 2:40pm 5A - Audience Q&A (GROUP 2)

5A - GROUP 3

2:40 - 2:45pm CBMT-18
Integrative cross platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma

2:45 - 2:50pm CBMT-06
Lower grade isocitrate dehydrogenase (IDH) mutant gliomas metabolically mimicking glioblastoma (GBM) express higher R:S 2-hydroxyglutarate ratios relative to non-GBM-mimicking IDH mutant gliomas
*Nejad R, Nassiri F, Mamatjian Y, Sim H-W, Chen E, Agnihotri S, Aldape K, Zadeh G*

2:50 - 2:55pm CSIG-34
PI3 kinase pathway activation promotes malignant progression in oligodendroglial tumors

2:55 - 3:00pm 5A - Audience Q&A (GROUP 3)

3:00 - 3:15pm BREAK
Preservation Hall

1:30 - 3:00pm CONCURRENT SESSION 5B

**Surgery/Radiation/Radiobiology and DNA Repair**  Grand Ballroom Carondelet

5B - GROUP 1

1:30 - 1:40pm SURG-02
A novel risk model to define the relative benefit of maximal extent of resection within prognostic groups in newly diagnosed glioblastoma

1:40 - 1:50pm RTHP-06
Randomized prospective trial of stereotactic radiosurgery versus chemotherapy for recurrent malignant glioma after second-line chemotherapy

1:50 - 2:00pm RDNA-18
TPS, a peptide inhibitor of aberrant and hyperactive CDKs/p25: a novel therapeutic approach against glioblastoma

2:00 - 2:10pm RDNA-05
Synthetic sensitization of MGMT-deficient tumor cells to temozolomide using ATR inhibitors
*Jackson C, Noorbakhsh S, Sundaram R, Kalathil A, Bindra R*

2:10 - 2:15pm DISCUSSANT  Pamela Jones

2:15 - 2:20pm 5B - Audience Q&A (GROUP 1)

5B - GROUP 2

2:20 - 2:25pm RTHP-08
Re-evaluating the sequencing of radiotherapy and chemotherapy in pediatric medulloblastoma

2:25 - 2:30pm RTHP-02
Impact of 18F-DOPA PET on radiotherapy target volumes for newly diagnosed MGMT unmethylated glioblastoma patients; preliminary results of a phase II dose-escalation trial

2:30 - 2:35pm RTHP-05
Non-operative treatment of non-germinomatous germ cell tumors of the pineal region
*Lee J, Cai LB, Lai M*

2:35 - 2:40pm 5B - Audience Q&A (GROUP 2)
**MAIN MEETING**

**SUNDAY, NOVEMBER 17**

**5B - GROUP 3**

2:40 - 2:45pm

RTHP-32

Reconsidering the prognostic impact of age, grade, and extent of resection on clinical outcomes of 1p/19q codeleted oligodendrogliomas after radiation therapy: a multi-institutional report

Lin A, Kane L, Molitoris J, Smith D, Badiyan S, Wang T, Kruser T, Huang J

2:45 - 2:50pm

SURG-13

Third harmonic generation (THG) imaging: A novel tool for intra-operative histologic analysis of fresh human glioma tissue


2:50 - 2:55pm

RTHP-04

Tumor recurrence or radiation necrosis following chemoradiation in patients with glioblastoma: Does pathology predict outcomes?


2:55 - 3:00pm

LTBK-04

Phase 1 trial of Wee1 kinase inhibitor Adavosertib (AZD1775) combined with radiation therapy for children with newly diagnosed diffuse intrinsic pontine glioma: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADV1217)


3:00 - 3:05pm

5B - Audience Q&A (GROUP 3)

3:05 - 3:15pm

BREAK

Preservation Hall

**1:30 - 3:00pm**

**CONCURRENT SESSION 5C**

**Neuro-Imaging**

Mardi Gras D-E

Moderators: Spyridon Bakas, Benjamin Ellingson

**5C - GROUP 1**

1:30 - 1:40pm

NIMG-33

Multicenter, prospective validation of automated intraoperative neuropathology using stimulated Raman histology and convolutoval neural networks


1:40 - 1:50pm

NIMG-75

WHO 2016 grade II glioma molecular subtypes have a distinct spatial distribution pattern


1:50 - 2:00pm

NIMG-40

Non-invasive in vivo signature of IDH1 mutational status in high grade glioma, from clinically-acquired multi-parametric magnetic resonance imaging, using multivariate machine learning

Bakas S, Rathore S, Nasrallah M, Akbari H, Binder Z, Min Ha S, Mamourian E, Morrisette J, O'Rourke D, Davatzikos C

2:00 - 2:05pm

DISCUSSANT

Kristin Swanson

2:05 - 2:10pm

5C - Audience Q&A (GROUP 1)

2:10 - 2:15pm

NIMG-79

Early treatment response assessment using O-(2-18F-fluoroethyl)-L-tyrosine (FET) PET compared to MRI in malignant gliomas treated with adjuvant temozolomide chemotherapy


2:15 - 2:20pm

NIMG-73

Radiomics of glioblastoma for predicting MGMT promoter methylation status and prognosis


2:20 - 2:25pm

NIMG-45

Multivariate pattern analysis of de novo glioblastoma patients offers in vivo evaluation of O6-methylguanine-DNA-methyltransferase (MGMT) promoter methylation status, compensating for insufficient specimen and assay failures

Rathore S, Bakas S, Nasrallah M, Akbari H, Bagley S, Ha SM, Mamourian E, Watt C, Binder Z, O'Rourke D, Davatzikos C

2:25 - 2:30pm

NIMG-26

Radiomic features of Glioblastoma on pre-treatment Gd-T1w MRI are predictive of response to chemo-radiation therapy and associated with AKT and apoptosis pathways


2:30 - 2:35pm

5C - Audience Q&A (GROUP 2)

5C - GROUP 3

2:35 - 2:40pm

NIMG-23

Deep learning for accurate, rapid, fully automatic measurement of brain tumor-associated abnormality seen on MRI

2:40 - 2:45pm
NIMG-68
MRI changes in newly diagnosed glioblastoma patients treated as part of a Phase II trial with bavituximab, radiation, and temozolomide

2:45 - 2:50pm
NIMG-27
Radiogenomic analysis of Glioblastoma reveals textural features from MRI that correlate with genomic immune score and are also predictive of chemo-radiation treatment response

2:50 - 2:55pm
NIMG-30
Preoperative predictors of malignancy in non-enhancing glioma in the era of molecular classification

2:55 - 3:00pm
5C - Audience Q&A (GROUP 3)

3:00 - 3:15pm
BREAK
Preservation Hall

3:15 - 5:10pm
CONCURRENT SESSION 6A

Pediatrics: Clinical and Basic Science Grand Ballroom Acadia - Bissonet
Moderators: Cassie Kline, Sabine Mueller

6A - GROUP 1

3:15 - 3:25pm
PDTM-20
Elucidating molecular pathogenic mechanisms of the histone H3.3 G34R mutation in pediatric high-grade gliomas (HGGs)
Hooge S, Garcia-Fabiani MB, Nunez FJ, Kadiyala P, Nunez F, Lowenstein PR, Castro MG
PEDIATRIC BASIC RESEARCH AWARD

3:25 - 3:35pm
PDCT-09
Phase 1/2 study of DSP-7888 in pediatric patients with malignant glioma

3:35 - 3:45pm
PDTM-27
Epigenetic loss of BAI1 expression in cerebellar granule neuron precursors inactivates the p53 tumor suppressor and facilitates medulloblastoma formation in the cerebellum.

3:45 - 3:55pm
PDTM-33
ATRX loss confers enhanced sensitivity to combined PARP inhibition and radiotherapy in paediatric glioblastoma models

3:55 - 4:05pm
PDTM-34
Targeting H3.3G34R/V re-wiring of the epigenome in pediatric glioblastoma of children and young adults

4:05 - 4:10pm
DISCUSSANT Tabitha Cooney

4:10 - 4:15pm
6A - Audience Q&A (GROUP 1)

6A - GROUP 2

4:15 - 4:20pm
PDTM-26
Dual therapy with PI3K inhibitor ZSTK-474 and MEK inhibitor trametinib via convection-enhanced delivery in a genetically-engineered mouse model of diffuse intrinsic pontine glioma
Chang B, Tosi U, Bhanu Maachani U, Voronina I, Schweitzer M, Wu L, Souweidane M

4:20 - 4:25pm
PDTM-21
Matching of single cell transcriptomics from cerebellar development identifies putative subgroup specific cells of origin for medulloblastoma

4:25 - 4:30pm
PDTM-13
Overexpression of MYC alone is sufficient to initiate group 3 medulloblastoma

4:30 - 4:35pm
PDTM-31
Drug screening linked to molecular profiling identifies novel dependencies in primary cultures of pediatric high grade glioma and DIPG
4:35 - 4:40pm  
**PDTM-12**  
**DLX2 transcripional regulation of central nervous system cell fate relevance to pediatric diffuse midline gliomas with Histone 3 mutations**  
Nevin M, Song X, Becher O, Underhill DA, Godbout R, Eisenstat D

4:40 - 4:45pm  
**6A - Audience Q&A (GROUP 2)**

4:45 - 4:50pm  
**PDTM-06**  
**ALK amplification and rearrangements are recurrent targetable events in glioblastoma**  

4:50 - 4:55pm  
**PDTM-28**  
The contribution of PAX genes as novel tumor suppressors in group 3 medulloblastoma

4:55 - 5:00pm  
**PDTM-18**  
**Activation of tumor-reactive T cells against brain stem glioma using hematopoietic stem cells**  
Flores C, Woodworth D, Moorley D, Moore G, Mitchell D

5:00 - 5:05pm  
**PDTM-11**  
**Activation of tumor-reactive T cells against brain stem glioma using hematopoietic stem cells**  
Flores C, Woodworth D, Moorley D, Moore G, Mitchell D

5:05 - 5:10pm  
**6A - Audience Q&A (GROUP 3)**

3:15 - 5:05pm  
**CONCURRENT SESSION 6B**

**Meningioma**  
*Grand Ballroom Carondelet*  
*Moderators: Ghazaleh Tabatabai, Gelareh Zadeh*

6B - Group 1

3:20 - 3:30pm  
**Invited Speaker: Patrick Wen**  
Opportunities in clinical trials for meningiomas

3:30 - 3:40pm  
**Invited Speaker: Kenneth Aldape**  
Precision diagnostics guiding menigioma care

3:40 - 3:50pm  
Pediatric menigiomas are characterized by distinct methylation profiles different from adult menigiomas

3:50 - 3:55pm  
**MNGI-36**  
Brain invasion in menigiomas previously classified as WHO grade I has limited impact on outcome

3:55 - 4:00pm  
**MNGI-28**  
Correlation of methylation class and genetic alterations with progression free survival in menigioma

4:00 - 4:05pm  
**MNGI-12**  
Expression of Programmed cell death ligand-1 (PD-L1) in menigioma: Clinical utility for prediction of tumor recurrence and association with hypoxic response and NFKB2 activation

4:05 - 4:10pm  
**6B - Audience Q&A (GROUP 1)**

6B - Group 2

4:10 - 4:15pm  
**MNGI-17**  
The ROAM / EORTC 1308 information study results: how qualitative research methods can optimize patient recruitment for menigioma trials

4:15 - 4:20pm  
**MNGI-18**  
Risk factors for pre- and postoperative seizures in menigioma patients identified by logistic regression analysis

4:20 - 4:25pm  
**MNGI-10**  
Predictors of early progression of surgically treated atypical menigiomas

4:25 - 4:30pm  
**MNGI-14**  
Loss of histone H3K27me3 identifies a subset of menigiomas with increased risk of recurrence

4:30 - 4:35pm  
**6B - Audience Q&A (GROUP 2)**
MAIN MEETING  SATURDAY, NOVEMBER 17

6B - Group 3
4:35 - 4:40pm  EXTH-63
Efficient ADCC-mediated killing of malignant meningioma cells using avelumab and an engineered high avidity natural killer cell line, haNK

4:40 - 4:45pm  MNGI-37
DMD genomic deletions characterize a subset of progressive/higher-grade meningiomas with poor outcome

4:45 - 4:50pm  MNGI-22
A prognostic index to predict the risk of active monitoring failure for incidentally-found asymptomatic meningiomas

4:50 - 4:55pm  MNGI-27
The long-term disease burden of meningioma patients: results on health-related quality of life, cognitive function, anxiety and depression

4:55 - 5:00pm  MNGI-07
The Anaplastic Meningioma International Consortium (AMiCo) retrospective study of treatment and outcome of patients with anaplastic meningiomas

5:00 - 5:05pm  6B - Audience Q&A (GROUP 3)

3:15 - 5:00pm  CONCURRENT SESSION 6C
RANO Update  Mardi Gras D-E
Chairs: Susan Chang, David Macdonald, Martin van den Bent, Michael Vogelbaum, Patrick Wen

3:15 - 3:20pm  Introduction
3:20 - 3:25pm  Brain metastases, Eudocia Quant Lee
3:25 - 3:35pm  Leptomeningeal disease, Manmeet Ahluwalia, Riccardo Soffietti
3:35 - 3:45pm  PET, Joerg Tonn
3:45 - 3:50pm  RAPNO, Kathy Warren
3:50 - 4:00pm  iRANO, Hideho Okada, David Reardon
4:00 - 4:08pm  NANO, Lakshmi Nayak, David Reardon
4:08 - 4:18pm  Meningiomas, Patrick Wen, Raymond Huang
4:18 - 4:25pm  Seizures - the next step - redesign outcome measures, Edward Avila
4:25 - 4:35pm  Patient reported outcome, Martin Taphoorn, Terri Armstrong
4:35 - 4:40pm  Steroids, Patrick Wen
4:40 - 4:50pm  Novel endpoints for low grade gliomas, Raymond Huang
4:50 - 4:55pm  Phase 0 trials in Neuro-Oncology, Michael Vogelbaum
4:55 - 5:00pm  Next steps

5:00 - 7:00pm  Industry Supported Symposium  Galeries 5-6
Not sponsored by The University of Texas MD Anderson Cancer Center
• Modern tumor board – translating molecular pathology into practice
Supported by Illumina

5:00 - 7:00pm  E-TALKS Interactive Electronic 4 Minute Presentations Followed By Traditional Poster Viewing and Discussions  Sheraton Hotel - Grand Ballroom
Group 1: Adult Therapeutics/Immunology
Group 2: Angiogenesis and Invasion/Radiation Biology and DNA Repair/Tumor Models/ Stem Cells/Epidemiology
Group 3: Health Outcomes/ Neurological Complications of Cancer and Cancer Therapy/ Quality of Life/ Radiotherapy/Surgical Therapy/CNS Metastases

5:00 - 7:00pm  POSTER SESSION Traditional Poster Viewing  Sheraton Hotel - Grand Ballroom

7:00 - 11:00pm  SNO GALA Held at Contemporary Arts Center (Separate Ticket Required)
**E-TALKS**  
5:00 - 7:00pm

**GROUP 1: Adult Therapeutics/Immunology**  
*Moderators: Howard Colman, Eudocia Quant Lee*

5:00 - 5:04pm  
**ATIM-07**  
Window-of-opportunity clinical trial of pembrolizumab in recurrent glioblastoma patients  

5:04 - 5:08pm  
**ATIM-23**  
Anti-CD27 agonist antibody varilimumab in combination with nivolumab for recurrent glioblastoma (rGBM): Phase 2 clinical trial results  
Reardon D, Kaley T, Iwamoto F, Baehring J, Subramaniam D, Rawls T, He Y, Keler T, Yellin M

5:08 - 5:12pm  
**ATIM-32**  
Personalized neoantigen-targeting vaccine generates robust systemic and intratumoral T cell responses in glioblastoma (GBM) patients  

5:12 - 5:16pm  
**ATIM-16**  
Phase 1 study results of M7824 (MS80011359C), a bifunctional fusion protein targeting TGF- and PD-L1, among patients with recurrent glioblastoma (rGBM)  

5:16 - 5:20pm  
**ATIM-37**  
Safety run-in results of a phase I/Ii study to evaluate the safety and clinical efficacy of atezolizumab (atezo; aPDL1) in combination with temozolomide (TMZ) and radiation in patients with newly diagnosed glioblastoma (GBM)  

5:20 - 5:24pm  
**ACTR-14**  
Phase I study of AZD1775 with radiation therapy (RT) and temozolomide (TMZ) in patients with newly diagnosed glioblastoma (GBM) and evaluation of intratumoral drug distribution (IDD) in patients with recurrent GBM  

5:24 - 5:28pm  
**ACTR-17**  
Evophophamide (TH-302) for recurrent GBM following bevacizumab failure, final results of a multicenter phase II study  

5:28 - 5:32pm  
**ACTR-64**  
Objective responses to chemotherapy in recurrent glioma do not predict better survival: A prospective analysis from the German Glioma Network  

5:32 - 5:36pm  
**ACTR-46**  
Higher doses of TTFields in the tumor are associated with improved patient outcome  
Ballo M, Bomzon Z, Urman N, Lavy-Shahaf G, Toms S

5:36 - 5:40pm  
**ACTR-15**  
Safety and preliminary activity of PT2385, a first-in-class HIF2-alpha inhibitor, planned interim analysis of an open label, single-arm phase II study in patients with recurrent glioblastoma  

5:40 - 5:44pm  
**IMMU-70**  
Global immune fingerprinting in glioblastoma reveals immune-suppression signatures associated with prognosis  

5:44 - 5:48pm  
**IMMU-38**  
Targeting hypoxia downstream signaling protein, CAIX for CAR-T cell therapy against glioblastoma (GBM)  

5:48 - 5:52pm  
**IMMU-16**  
Guadecitabine (SGI-110) enhances MHC class I and tumor antigen expression on murine C57BL/6-6syngeneic glioma and DIPG models  

5:52 - 5:56pm  
**IMMU-34**  
A Balanced Tryptophan Diet Leads to Maximal Immunotherapeutic Efficacy in Glioblastoma Models  

5:56 - 6:00pm  
**IMMU-25**  
Programmed cell death-ligand 1 (PD-L1) is not expressed in diffuse intrinsic pontine glioma (DIPG) tumor cells  

6:00 - 6:04pm  
**ACTR-55**  
Tumor volume as a predictor of response to anti-EGFR ADC ABT-414  
5:00 - 5:04pm
ANGI-08
Targeting the RhoGEF Beta-Pix to enhance the activity of bevacizumab in glioblastoma: A nanoparticle mediated gene silencing approach

5:04 - 5:08pm
ANGI-06
The matrix protein Thrombospondin-1 is a downstream target of TGF-β induced microtube formation in glioblastoma

5:08 - 5:12pm
TMOD-27
Humanized microbiome mouse models to enhance immunotherapy in glioblastoma

5:12 - 5:16pm
TMOD-33
Establishment and preliminary evaluation of bevacizumab-resistant glioma xenograft models
Keir S, Waitkus M, Roskoski M, Friedman H, Bigner D, Yan H, Ashley D

5:16 - 5:20pm
TMOD-09
Targeting the PI3K-mTOR pathway and elucidating mechanisms of resistance in a novel and relevant animal model of Glioblastoma.

5:20 - 5:24pm
TMOD-03
GliomaPDOX: A molecularly diverse library of direct-from-patient orthotopic glioma xenografts recapitulates intratumor heterogeneity

5:24 - 5:28pm
ACTR-12
Preliminary safety and efficacy of a phase II trial of 18F-DOPA PET-guided, dose-escalated radiotherapy in the treatment of glioblastoma

5:28 - 5:32pm
TMOD-31
Novel heterogeneous glioblastoma models to optimize human tumoricidal neural stem cell therapy
Satterlee A, Dunn D, Hagler S, Lo D, Hingtgen S

5:32 - 5:36pm
STEM-07
Non-canonical regulation of SOX2 by the TRIM26 E3 ubiquitin ligase in glioblastoma stem-like cells
Mathiokozera T, Taiwo R, Mao D, Salehi A, Gujar A, Kim A

5:36 - 5:40pm
STEM-24
Identification of Serpin B3 as a junctional adhesion molecule a binding partner in glioblastoma cancer stem cells
Volovetz J, Turaga S, Noik U, Lathia J

5:40 - 5:44pm
STEM-01
Prospective analysis of cancer stem cell drug response assay for glioblastoma patients

5:44 - 5:48pm
STEM-13
Hypoxic induction of vasorin mediates glioma stem cell-endothelial cell interactions in the perivascular niche
Yu J, Yu X, Burrows, A, Bao S

5:48 - 5:52pm
STEM-12
Downregulation of H-Ferritin expression using multivalent cationic liposomes results in increased radiation sensitivity in patient derived glioma initiating cells
Ravi V, Madhankumar A, Slagle-Webb B, Connor J

5:52 - 5:56pm
EPID-01
Associations of timing of adjuvant therapies, radiation fractions and radiation doses with glioblastoma survival: A retrospective cohort analysis using the National Cancer Database and SEER-Medicare database
Zhu P, Du X, Esquenazi V, Zhu J-J
GROUP 3: Health Outcomes/Neurological Complications of Cancer and Cancer Therapy/Quality of Life/Radiotherapy/Surgical Therapy/CNS Metastases

Moderators: Pim French, Raju Raval

5:00 - 5:04pm
HOUT-16
The cost effectiveness of Tumor Treating Fields treatment for patients with newly diagnosed glioblastoma based on the EF-14 trial
Guzauskas G, Wang BCM, Polloff E, Stieber VW, Garrison L

5:04 - 5:08pm
HOUT-35
Retrospective analysis of outcomes in hospitalized malignant brain neoplasm patients with status epilepticus
Lobbous M, Gupta S, Warren P

5:08 - 5:12pm
NCMP-03
Risk factors for surgical site infections after craniotomy for primary brain tumors
Krafft PR, Agoris C, Tran Q, Sahebjam S, Tran N

5:12 - 5:16pm
NCMP-22
Treatment-related adverse effects in patients with malignant glioma: establishment of key features for pseudoprogression and treatment-induced necrosis.

5:16 - 5:20pm
QOLP-02
Insurance status impacts the economic burden and survival of glioblastoma patients with health insurance

5:20 - 5:24pm
QOLP-25
Quality of life following re-irradiation for recurrent high grade glioma

5:24 - 5:28pm
RTHP-21
Characterization of radiation therapy effects on cerebral vasculature in pediatric brain tumor survivors
Avadiappan S, Morrison M, Jakary A, Felton E, Mueller S, Lupo J

5:28 - 5:32pm
RTHP-07
Transcription factor networks of oligodendrogliomas (IDH-mutant and 1p/19q codeleted) treated with adjuvant radiotherapy or observation informs prognosis
So J, Moraes F, Mamajian Y, Aldape K, Zadeh G

5:32 - 5:36pm
RTHP-10
Less is more or bigger is better? Radiation treatment volume for glioblastoma patients does not impact survival

5:36 - 5:40pm
SURG-06
LASER ABLATION IN ABNORMAL NEUROLOGICAL TISSUE USING ROBOTIC NEUROBLATE SYSTEM (LAANTERN) REGISTRY

5:40 - 5:44pm
SURG-07
Between-hospital variation in mortality and survival after glioblastoma surgery

5:44 - 5:48pm
SURG-05
Navigated intra-operative 2-D ultrasound vs standard neuronavigation in high grade glioma surgery

5:48 - 5:52pm
IMMU-26
Visualizing tumor cell - lymphocyte interactions in the brain metastatic cascade using in vivo two photon microscopy

5:52 - 5:56pm
CMET-28
Impact of disease site, size and surgical resection on survival from metastatic CNS neuroblastoma

5:56 - 6:00pm
CMET-19
Clinical risk assessment score to estimate the likelihood of pseudoprogression versus tumor growth following stereotactic radiosurgery for brain metastases.
Skeie B, Øivind Enger P, Pedersen P-H, Olve Skeie G

6:00 - 7:00pm
E-Talk presenters move to their designated posters in the general poster session for further discussion
SUNRISE SESSIONS  7:00 - 8:30am

Brain Tumor Stem Cells as Drivers of Therapeutic Resistance  Grand Ballroom Carondelet
Petra Hamerlik (Chair)
- Genomic instability and replication stress in glioblastoma-derived cancer stem cells, Petra Hamerlik
- Glioma stem cell-derived pericytes and the blood-tumor barrier, Shideng Bao
- Tumor edge-located recurrence-initiating cells, Ichiro Nakano
- How the genetic make-up of brain tumor stem cells mediates the response to therapeutics, Maria Castro

Viral Therapies in Brain Tumors  Grand Ballroom Acadia
Juan Fueyo (Chair)
- Delta-24-RGD in combination with positive regulators of the immune synapsis for gliomas in adults and children, Juan Fueyo
- Oncolytic measles virus in GBM treatment: harnessing permissiveness and proinflammatory responses, Eva Galanis
- Treatment of pontine gliomas with oncolytic adenoviruses, Marta Alonso
- Oncolytic rhabdovirus vaccine therapy for GBM, David Stodlj

The Use of Machine Learning Methods in Brain Tumor Imaging  Galeries 1-2
Dafna Ben Bashat (Chair)
- Application of radiomics & deep-learning in brain tumor imaging, Philipp Kickingereder
- Decoding tumour phenotype of brain tumours by noninvasive imaging using a quantitative radiomics approach, Philippe Lambin
- Improving therapy response assessment of high grade gliomas using machine learning classifications, Dafna Ben Bashat
- Radiomics for immune assessment in brain tumors, Arvind Rao

Reproductive and Women’s Neuro-Oncology  Mardi Gras F-H
NaTosha Gatson (Chair)
- Neuro-Oncology in Women (N.O.W.): Introduction, overview, and a clinical case evaluation, NaTosha Gatson
- Epidemiological and biological basis of CNS tumors relevant to neuro-oncology in women, Priscilla Brastianos
- Best clinical practice: Oncofertility ethics and guidelines relevant to neuro-oncology in women, Terri Woodard
- Genetically disparate cells persist long-term and reach the brain: implications for neuro-oncology, J. Lee Nelson

Targeting Gliomas, Perspective from China  Galeries 5-6
Shi-Yuan Cheng (Chair)
- Autophagy in glioblastoma: critical for tumorigenesis and viable target for combination therapy, Shi-Yuan Cheng
- Developing anti-vascular therapy for GBM through dissecting microcirculation pattern, Zhong-Ping Chen
- Mutational landscape reveals MET alteration as a drug target in secondary glioblastoma, Tao Jiang
- Are IDH wt diffuse astrocytomas just glioblastoma in disguise? Ho-Keung Ng

Circulating Biomarkers  Grand Ballroom Bissonet
Chetan Bettegowda (Chair)
- Liquid biopsy for GBM - the holy grail or a bridge too far, Amit Ray
- Blood based assays for diagnosis and stratification of glioma patients, Leonora Balaj
- Blood test for brain tumors, Brian Nahed
- CSF based liquid biopsies for brain tumors, Chetan Bettegowda

Meningiomas: Molecular Advances and Targeted Therapy  Mardi Gras D-E
Ian Dunn, Gelareh Zadeh (Co-chairs)
- Limits of surgery and radiation therapy for meningiomas  Point-Counter-Point
  Role of surgery and pushing boundaries of resection, William Couldwell
  Outcomes and limits of surgery, Michael McDermott
- Advances in multidisciplinary therapies for meningioma  Point-Counter-Point
  Moving towards targeted therapies for meningiomas, Michael Weller
  The continued role of radiation therapy, Leland Rogers
- State-of-the-art diagnostics and prognostic markers  Point-Counter-Point
  Nomogram to predict outcome and guide therapy, Farshad Nassiri
  Imaging advances of meningiomas, Roland Goldbrunner
**Concurrent Session 7A: Adult Clinical Trials II**

*Grand Ballroom Acadia - Bissonet*

**Moderators:** John de Groot, Evanthia Galanis

### 7A - Group 1

**8:45 - 8:55am**

A phase I study of cytosine deaminase-expressing neural stem cells (CD-NSCs) administered intracranially and in combination with oral 5-fluorocytosine (5-FC) and leucovorin in patients with recurrent high grade glioma

*Portnow J, Synold T, Badie B, Blanchard S, Kilpatrick J, Tirughana R, Metz M, Tran V, Aboody K*

### 8:55 - 9:05am

Efficacy and safety of dabrafenib + trametinib in patients with recurrent/refractory BRAF V600E–mutated high-grade glioma (HGG)


### 9:05 - 9:15am

Integrated clinical experience with ONC201 in previously-treated H3 K27M-mutant glioma patients


### 9:20 - 9:25am

**DISCUSSANT:** Evanthia Galanis

### 7A - Group 2

**9:25 - 9:30am**

A phase II study of apatinib plus temozolomide in adults with refractory recurrent high-grade gliomas

*Zhang J, Ge J, Li C*

### 9:30 - 9:35am

Targeting myeloid derived suppressor cells: Phase 0/1 trial of low dose capecitabine + bevacizumab in patients with recurrent glioblastoma

*Peereboom D, Lathia J, Alban T, Mohammadi A, Ahluwalia M, Brewer C, Vogelbaum M*

### 9:35 - 9:40am

Patients with EGFR amplification but without EGFRvIII expression have improved benefit compared to those with EGFRvIII expression in samples of the INTEL-LANCE 2/EORTC 1410 randomized phase II trial


### 9:40 - 9:45am

Phase II trial of temozolomide and TRC 102, base excision repair inhibitor, in bevacizumab naive glioblastoma at first recurrence


### 9:45 - 9:50am

**7A - Audience Q&A (Group 2)**

### 7A - Group 3

**9:50 - 9:55am**

A phase 1, multicenter, open-label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed WHO grade IV malignant glioma (glioblastoma, ndGBM): Full enrollment results

*Bota DA, Kesari S, Piccioni D, Aregawi D, Roth P, Stupp R, Desjardins A, Reich SD, Elias I, Li M, Levin N, Winograd B, Mason W*

### 9:55 - 10:00am

Open-label phase 1 clinical trial testing personalized and targeted skull remodeling surgery to maximize TTFields intensity for recurrent glioblastoma — interim analysis and safety assessment (OptimalTTF-1)


### 10:00 - 10:05am

A single arm phase 2 study of the dual mTORC1/mTORC2 inhibitor vistusertib provided on an intermittent schedule for neurofibromatosis 2 patients with progressive or symptomatic meningiomas

*Plotkin S, Jordan J, Beauchamp R, Muzikansky A, Stemmer-Rachamimov A, Ramesh V*

### 10:05 - 10:10am

Short-term bevacizumab for recurrent glioblastomas

*Matsutani T, Hirono S, Iwadate Y*

### 10:10 - 10:15am

**7A - Audience Q&A (Group 3)**

### 10:15 - 10:30am

**BREAK**

*Preservation Hall*
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Presenters</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:45 - 10:15am</td>
<td><strong>CONCURRENT SESSION 7B</strong></td>
<td><strong>Molecular Pathology/Stem Cells</strong> Grand Ballroom Carondelet</td>
<td><strong>Moderators:</strong> Karen Aboody, Charles Eberhart</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>ANDREW PARSA YOUNG INVESTIGATOR AWARD AND EANO/SNO TRAVEL SCHOLARSHIP AWARD</strong></td>
<td></td>
</tr>
<tr>
<td>9:05 - 9:15am</td>
<td>STEM-29</td>
<td>Unsaturated fatty acid (UFA) metabolism regulates membrane-endolysosome-nuclear inter-organelle communication in glioma stem cells</td>
<td>Hu J</td>
</tr>
<tr>
<td>9:15 - 9:20am</td>
<td></td>
<td><strong>DISCUSSANT Ichiro Nakano</strong></td>
<td></td>
</tr>
<tr>
<td>9:30 - 9:35am</td>
<td>PATH-32</td>
<td>Brain tumor classification updates from cIMPACT-NOW, the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Classification</td>
<td>Louis D, Brat D, Ellison D</td>
</tr>
<tr>
<td>9:35 - 9:40am</td>
<td>PATH-13</td>
<td>The origin of human glioblastoma (IDH wildtype) is not the location of the tumor but the subventricular zone</td>
<td>Kong S-G, Lee JH, Yoon SJ, Lee J-H, Kim SH, Kim EH, Chang JH, Lee JH</td>
</tr>
<tr>
<td>9:45 - 9:50am</td>
<td>7B - Audience Q&amp;A (GROUP 2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 - 10:05am</td>
<td>STEM-28</td>
<td>Tissue factor promotes the glioma stem cell phenotype, and is suppressed by mutant IDH1</td>
<td>Horbinski C, Unruh D, Mirkov S, Wray B, Lamano J, Scholtens D, Sarkaria J, James D</td>
</tr>
<tr>
<td>10:10 - 10:15am</td>
<td>7B - Audience Q&amp;A (GROUP 3)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:15 - 10:30am</td>
<td></td>
<td><strong>BREAK</strong> Preservation Hall</td>
<td></td>
</tr>
</tbody>
</table>
### 7C - GROUP 1

#### 8:45 - 8:55am

**CMET-20**

**Evidence of CNS response of pembrolizumab for leptomeningeal carcinomatosis at a single cell resolution**


#### 8:55 - 9:05am

**CMET-45**

**Checkpoint blockade immunotherapies for melanoma brain metastases: improved survival outcomes in a national cohort**

*Lorquescu J, Harary M, Zogg C, Ligon K, Hodi S, Aizer A, Reardon D, Smith T*

#### 9:05 - 9:15am

**CMET-39**

**Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: a randomized, open-label trial**


#### 9:15 - 9:25am

**CMET-30**

**Brain metastases from EGFR-mutated NSCLC which had acquired resistance to EGFR-TKI. “Less-frequent T790M and preserved response to other TKIs”**

*Iuchi T, Sakaida T, Hasegawa Y, Yoshida Y, Ashinuma H, Mizuno S, Setoguchi T, Shingoji M*

#### 9:25 - 9:30am

**DISCUSSANT: David Peereboom**

#### 9:30 - 9:35am

**7C - Audience Q&A (GROUP 1)**

### 7C - GROUP 2

#### 9:35 - 9:40am

**CMET-18**

**Risk factors for cerebral edema after stereotactic radiosurgery for brain metastases**

*Aalattar A, Hirshman B, Joshi R, Chen C*

#### 9:40 - 9:45am

**CMET-46**

**Initial clinical and advanced imaging outcomes from a multi-institutional phase I dose-escalation trial of RRx-001 plus whole brain radiation for patients with brain metastases**


#### 9:45 - 9:50am

**CMET-27**

**Outcomes of lung cancer patients with leptomeningeal metastases in the targeted therapy era**

*Nevel K, Cowan A, Reiner A, Ogilvie S, Skakodub A, Distefano N, Pentsova E, Boire A*

#### 9:50 - 9:55am

**7C - Audience Q&A (GROUP 2)**

### 7C - GROUP 3

#### 9:55 - 10:00am

**STEM-03**

**Novel metastatic brain tumor targets isolated through phage display biopanning against brain metastasis-initiating cells**

*Kim J, Boo S, Rich JN, Liu J*

#### 10:00 - 10:05am

**CMET-21**

**The role of brain metastasis free interval in patients with brain metastases of breast carcinoma**

*Hulsbergen A, Lamba N, Claes A, Kavouridis V, Smith T, Verhoeff J, Broekman M*

#### 10:05 - 10:10am

**CMET-22**

**Intrathecal (IT) Tratzuzumab (T) for the treatment of leptomeningeal metastases (LM) in patients (pts) with human epidermal growth factor receptor 2-positive (HER2+) cancer : A multicenter Phase 1/2 study**


#### 10:10 - 10:15am

**7C - Audience Q&A (GROUP 3)**

#### 10:15 - 10:30am

**BREAK**

**Preservation Hall**

### 8A - GROUP 1

#### 10:30 - 12:15pm

**CONCURRENT SESSION 8A**

**Drug Discovery/Drug Resistance/Tumor Models**

*Grand Ballroom Acadia - Bissonet*

**Moderators: Jann Sarkaria, Jennifer Yu**

#### 10:30 - 10:40am

**TMOD-36**

**Precise investigation of cancer stem cells in a mouse glioblastoma model**

10:40 - 10:50am Activation of FGF signaling pathway confers resistance to EGFR inhibition in GBM  
Guo G, Gong K, Sarkaria J, Habib A

10:50 - 11:00am Ciliary protein ARL13B promotes chemoresistance by modulate glioblastoma purine biosynthesis  
Shireman J, Atashi F, Park C, Warneke L, Miska J, Ahmed A

11:00 - 11:10am Can rare SOX9-positive cells incite MYC-driven medulloblastoma recurrence?  

11:00 - 11:10am DISCUSSANT  
Eric Holland

11:15 - 11:20am 8A - Audience Q&A (GROUP 1)

11:20 - 11:25am Preventing the emergence of temozolomide resistance in glioblastoma by PARP-1 inhibition  
Yuan A, Bering E, Cairncross J, Blough M

11:25 - 11:30am Novel bispecific activator of macrophages for the treatment of glioblastoma  
Salgado M, Schaller T, Gedeon P, Snyder D, Archer G, Sanchez-Perez L, Sampson J

11:30 - 11:35am Molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium  

11:35 - 11:40am Patient-derived brain tumour iPSCs: models for investigating glioma stemness and drug discovery  

11:40 - 11:45am DRD5 is a modulator of glioma susceptibility to DRD2 antagonism by QNC201  

11:45 - 11:50am 8A - Audience Q&A (GROUP 2)

11:50 - 11:55am Dynamic kinome profiling of genetically-defined, EGFRvIII-driven murine astrocyte models of glioblastoma reveals targets for dual kinase inhibitor therapy  

11:55 - 12:00pm In vivo functional genomics identifies drivers of chemoresistance in medulloblastoma  

12:00 - 12:05pm ZEB1-mediated invasive mesenchymal transition at the single cell level promotes anti-angiogenic therapy resistance in glioblastoma  

12:05 - 12:10pm Mutant IDH1 promotes glioma formation in vivo  
Yu D, Boekholder R, VanBrocklin M, Sonnen J, Colman H, Holmen S

12:10 - 12:15pm 8A - Audience Q&A (GROUP 3)

10:30 - 12:15pm CONCURRENT SESSION 8B

Practical & Applied Neuro-Oncology II  Grand Ballroom Carondelet
Moderators: David Eisenstat, Christine Siegel

10:30 - 10:40am Cost effectiveness of treating glioblastoma patients age 65 years or older with Tumor Treating Fields plus temozolomide versus temozolomide alone  
Guzauskas G, Wang BCM, Pollom E, Steiber VW, Garrison L

10:40 - 10:50am Using germine variants to predict glioma risk and identify glioma subtype pre-operatively  

10:50 - 11:00am Using germline variants to predict glioma risk and identify glioma subtype pre-operatively  

11:00 - 11:10am ZEB1-mediated invasive mesenchymal transition at the single cell level promotes anti-angiogenic therapy resistance in glioblastoma  

11:10 - 11:15am DISCUSSANT  
Eric Holland

11:15 - 11:20am 8A - Audience Q&A (GROUP 1)

11:20 - 11:25am Preventing the emergence of temozolomide resistance in glioblastoma by PARP-1 inhibition  
Yuan A, Bering E, Cairncross J, Blough M

11:25 - 11:30am Novel bispecific activator of macrophages for the treatment of glioblastoma  
Salgado M, Schaller T, Gedeon P, Snyder D, Archer G, Sanchez-Perez L, Sampson J

11:30 - 11:35am Molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium  

11:35 - 11:40am Patient-derived brain tumour iPSCs: models for investigating glioma stemness and drug discovery  

11:40 - 11:45am DRD5 is a modulator of glioma susceptibility to DRD2 antagonism by QNC201  

11:45 - 11:50am 8A - Audience Q&A (GROUP 2)

11:50 - 11:55am Dynamic kinome profiling of genetically-defined, EGFRvIII-driven murine astrocyte models of glioblastoma reveals targets for dual kinase inhibitor therapy  

11:55 - 12:00pm In vivo functional genomics identifies drivers of chemoresistance in medulloblastoma  

12:00 - 12:05pm ZEB1-mediated invasive mesenchymal transition at the single cell level promotes anti-angiogenic therapy resistance in glioblastoma  

12:05 - 12:10pm Mutant IDH1 promotes glioma formation in vivo  
Yu D, Boekholder R, VanBrocklin M, Sonnen J, Colman H, Holmen S

12:10 - 12:15pm 8A - Audience Q&A (GROUP 3)
10:50 - 11:00am  Effect of health disparities on overall survival of patients with glioblastoma  
EPID-08

11:00 - 11:05am  DISCUSSANT Jeffrey Wefel

11:05 - 11:10am  8B - Audience Q&A (GROUP 1)

11:10 - 11:15am  Incidence patterns of primary brain and other central nervous system tumors in Appalachia  
EPID-15

11:15 - 11:20am  Leveraging genomic data to identify risk factors for childhood ependymoma  
EPID-04

11:20 - 11:25am  Association between treatment facility volume and mortality in patients with glioblastoma (GBM): A large national analysis  
HOUT-23

11:25 - 11:30am  Real-word evaluation of the impact of radiotherapy and chemotherapy in elderly patients with glioblastoma based on age and performance status: A National Cancer Database analysis  
HOUT-21

11:30 - 11:35am  8B - Audience Q&A (GROUP 2)

HOUT-03

11:40 - 11:45am  Characterization of symptom burden in minority patients with CNS tumors: a report from the neuro-oncology branch (NOB) natural history study (NHS)  
HOUT-12

11:45 - 11:50am  Progression of IDH mutant glioma after first recurrence: development of a feasible clinical trial endpoint in the recurrent setting  
EPID-11

11:50 - 11:55am  8B - Audience Q&A (GROUP 3)

11:55 - 12:00pm  Effects of treatment and social demographics on adult medulloblastoma survival  
EPID-02

12:00 - 12:05pm  Patient Reported Outcomes Measurement Information System (PROMIS) screening for anxiety & depression in central nervous system (CNS) cancer: large cohort report from the Neuro-Oncology Branch Natural History Study (NOB-NHS).  
QOLP-26

12:05 - 12:10pm  A neuro-oncology caregiver support group, an effective way to provide emotional support for caregivers  
QOLP-08

12:10 - 12:15pm  8B - Audience Q&A (GROUP 4)

10:30 - 12:15pm  CONCURRENT SESSION 8C

Immunology – Preclinical and Clinical II  Mardi Gras D-E
Moderators: Annick Desjardins, David Reardon

8C - GROUP 1

10:30 - 10:40am  Multidimensional characterization of immune cell populations in the glioma tumor microenvironment reveals a predominant proportion of cells derived from the myelo-monocytic lineage  
IMMU-21
<table>
<thead>
<tr>
<th>Time</th>
<th>Session/Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50 - 11:00am</td>
<td>High rate of objective anti-tumor response in 9 patients with glioblastoma after viro-immunotherapy with oncolytic parvovirus H-1 in combination with bevacizumab and PD-1 checkpoint blockade <strong>Geleaney K, Bartsch A, Weiss C, Bernhard H, Marchini A, Rommelaere J</strong></td>
</tr>
<tr>
<td>11:00 - 11:05am</td>
<td><strong>DISCUSSANT</strong>: Peter Fecci</td>
</tr>
<tr>
<td>11:05 - 11:10am</td>
<td><strong>8C - Audience Q&amp;A (GROUP 1)</strong></td>
</tr>
<tr>
<td>11:30 - 11:35am</td>
<td><strong>8C - Audience Q&amp;A (GROUP 2)</strong></td>
</tr>
<tr>
<td>11:45 - 11:50am</td>
<td>Preventing T-cell S1P1 internalization obviates bone marrow T cell sequestration and improves immunotherapeutic efficacy in GBM <strong>Chongsathidikiet P, Woroniecka K, Dechant C, Kemeny H, Cui X, Wilkinson D, Fecci P</strong></td>
</tr>
<tr>
<td>11:50 - 11:55am</td>
<td><strong>8C - Audience Q&amp;A (GROUP 3)</strong></td>
</tr>
<tr>
<td>12:00 - 12:05pm</td>
<td>Phase 2 study of ERC1671 plus bevacizumab vs bevacizumab plus placebo in recurrent GBM interim results and correlations with CD4+ T lymphocyte counts <strong>Bota DA, Chung J, Dandekar M, Carrillo JA, Kong X, Fu DB, Hsu FPK, Schönthal AH, Hofman FM, Chen TC, Zidovetzki R, Pretto C, Strik A, Schijns VEJC, Stathopoulos A</strong></td>
</tr>
<tr>
<td>12:10 - 12:15pm</td>
<td><strong>8C - Audience Q&amp;A (GROUP 4)</strong></td>
</tr>
<tr>
<td>12:15 - 12:30pm</td>
<td><strong>Highlights of SNO 2018 and Announcement of Poster Awards</strong>: Grand Ballroom Acadia - Bissonet <strong>Frank Furnari, Daphne Haas-Kogan, Vinay Puduvalli</strong></td>
</tr>
<tr>
<td>12:30pm</td>
<td><strong>ADJOURN</strong></td>
</tr>
</tbody>
</table>
MAIN MEETING

SUNDAY, NOVEMBER 18

FILLER OR HIGHLIGHT SOMETHING
The Society for Neuro-Oncology gratefully acknowledges the SNO Platinum Partners listed below. Their on-going support allows SNO to fulfill its mission to advance neuro-oncology research and education.

The Society for Neuro-Oncology wishes to express appreciation to the organizations listed below for their promotional support of this meeting.

**Benefactor Level**

- BRAINLAB
- cernfoundation™
- Nativis
- Orbus Therapeutics, Inc.

**Contributor Level**

- BeiGene
- Celgene
- enbrain
- Genentech
- illumina
- DC VAX
- Tocagen

The conference organizing committee wishes to express appreciation to the following companies for their commitment to continuing medical education by providing an educational grant in support of this conference.

- AbbVie
- Celgene